An Open Label Multi-Center Study of the Effects of GC4419 When Administered to Reduce the Incidence and Severity of Severe Oral Mucositis Associated With Chemo RT for Locally Advanced, Non-Metastatic Head and Neck Cancer
Phase: PHASE2
Conditions: Head and Neck Cancer, Oral Mucositis
Sponsor: Galera Therapeutics, Inc.

CLINICAL STUDY PROTOCOL 
Study Title: 
An Open Label Multi-Center Study of the Effects of Superoxide 
Dismutase Mimetic GC4419 when Administered to Reduce the 
Incidence and Severity of Severe Oral Mucositis (SOM) 
Associated with Chemoradiotherapy for Locally Advanced, Non-
Metastatic Head and Neck Cancer  
 
 
Sponsor: 
Galera Therapeutics, Inc. 
2 West Liberty Boulevard, Suite 110 
Malvern, PA 19355 USA 
 
 
IND Number: 
111,539 
 
 
Protocol ID: 
GTI-4419-202 
EudraCT Number: 
2019-002745-38 
 
 
Medical Monitor: 
Jon T. Holmlund, MD 
 
 
Protocol Version/Date: 
 
Previous Version/Date: 
Version 3.0/ 02September2020 
 
Version 2.0/ 03August2020 
Version 1.0/ 23July2019 
 
 
CONFIDENTIAL INFORMATION 
The information contained in this document is proprietary to Galera Therapeutics, Inc. The information is 
to be used only in connection with review of, or participation in, authorized clinical studies of the 
investigational drug described in the protocol. Disclosure of the information to others not under obligations 
to maintain this information in confidence is prohibited without written authorization from Galera 
Therapeutics, Inc. with the exception that, to the extent necessary to obtain informed consent from those 
persons to whom the drug may be administered, a general protocol description may be disclosed to such 
potential subjects. 
 
 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 2 of 73 
STUDY ACKNOWLEDGEMENT 
Study Title: An Open Label Multi-Center Study of the Effects of Superoxide Dismutase Mimetic 
GC4419 when Administered to Reduce the Incidence and Severity of Severe Oral Mucositis 
(SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and 
Neck Cancer 
Protocol No. GTI-4419-202 
Final Protocol Date: 02September2020 
This protocol has been approved by Galera Therapeutics, Inc. The following signature 
documents this approval. 
 
Jon T. Holmlund, MD 
Chief Medical Officer 
Galera Therapeutics, Inc. 
Investigator Statement: 
I have read the attached protocol dated 02September2020 and agree to abide by all provisions set 
forth therein. I will provide copies of the protocol and other pertinent information to all 
individuals responsible to me who will assist with the study. 
I agree to comply with the International Council for Harmonisation (ICH), Tripartite Guideline 
on Good Clinical Practice (GCP), applicable Food and Drug Administration (FDA) 
regulations/guidelines set forth in 21 Code of Federal Regulations (CFR) Parts 11, 50, 54, 56, 
and 312 and other applicable regulatory authority requirements. 
I agree to ensure that Financial Disclosure Statements will be completed before study initiation, 
during the studies if there are changes that affect my financial disclosure status, and one year 
after study completion by: 
• myself (including, if applicable, my spouse [or legal partner] and dependent children) 
• my sub-investigators (including, if applicable, their spouses [or legal partners] and 
dependent children) 
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Galera Therapeutics, Inc. 
The Sponsor or its designee will have access to source documentation from which case report 
forms have been completed. 
__________________________________          __________________________ 
Signature of Principal Investigator 
 
   Date (DD MMM YYYY) 
 
__________________________________ 
Printed Name of Principal Investigator 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 3 of 73 
1. 
SYNOPSIS 
Name of Sponsor/Company: Galera Therapeutics, Inc.  
Name of Investigational Product: GC4419 (avasopasem manganese) 
Name of Active Ingredient: 
GC4419 (avasopasem manganese) 
Title of Study: 
An Open Label Multi-Center Study of the Effects of Superoxide Dismutase Mimetic GC4419 when 
Administered to Reduce the Incidence and Severity of Severe Oral Mucositis (SOM) Associated with 
Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer 
Number of Study Center(s): 
Approximately 30 centers in selected countries in Europe  
Estimated Enrollment Period:  
Approximately 12 months 
Studied period (years): 
First subject enrolled: June 2020 
Estimated date last subject enrolled: 4th quarter 2020 
Estimated date for primary results: 2nd quarter 2021 
Phase of 
development: 2 
Objectives: 
Primary Objective: 
• 
To assess the safety and tolerability of GC4419 administered intravenously (IV) to subjects 
receiving post-operative or definitive therapy with single-agent cisplatin plus Intensity-
Modulated Radiation Therapy (IMRT) for locally advanced, non-metastatic squamous cell 
carcinoma (SCC) of the head and neck 
Secondary Objective: 
• 
To assess the incidence of severe oral mucositis (SOM; World Health Organization Grade 3 
or 4) in the study population  
Endpoints: 
Primary Endpoint: 
• 
Frequency, duration, and severity of AEs and serious AEs (SAEs); 
• 
Incidence and shifts of clinically significant laboratory abnormalities 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 4 of 73 
Secondary Endpoints: 
• 
Cumulative incidence of SOM, defined as any occurrence of WHO Grade 3-4 OM, from the 
first IMRT fraction through the end of the study treatment period (last day of IMRT) 
• 
Cumulative incidence of WHO Grade 4 OM and days of Grade 4 OM from the first IMRT 
fraction through the end of the study treatment period (last day of IMRT) 
• 
Cumulative incidence of SOM, and days of SOM, from the first IMRT fraction through two 
weeks after the end of IMRT 
Methodology: 
GTI-4419-202 is an open-label, multi-center international study conducted to evaluate the effects of 
GC4419 when administered IV in combination with IMRT/cisplatin to subjects with head and neck 
cancer, who are at high risk for SOM. 
Subjects will receive 90 mg GC4419 per day (60 min IV infusion to complete within 4 hours prior to 
IMRT), concurrent with daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over 
approximately 7 weeks, plus cisplatin administered 100 mg/m2 once every three weeks for 3 doses or 
40 mg/m2 once weekly for 6-7 doses (Investigator’s choice) 
Note: Planned radiation fields must include at least 2 oral sites (left and right buccal mucosa, floor 
of mouth, left and right lateral tongue, soft palate) with each site receiving a cumulative dose of at 
least 50 Gy. 
If IMRT is not administered on any given day due to a treatment break or unforeseen circumstances, 
GC4419 should not be administered on that day. 
All subjects will be assessed twice weekly for OM per WHO grading criteria until 28 days post end 
of study treatment period (last day of IMRT). 
Number of subjects (planned): 
Up to 70 total subjects 
Diagnosis and main criteria for inclusion: 
Inclusion Criteria: 
1. Pathologically-confirmed diagnosis of locally advanced squamous cell carcinoma of the head and 
neck that will be treated with cisplatin plus concurrent IMRT. 
Note: Patients with unknown primary tumors whose treatment plan matches the requirements 
specified in Inclusion Criteria #2 and #3 below are eligible for the study. 
2. Treatment plan to receive a continuous course of IMRT delivered as single daily fractions of 2.0 
to 2.2 Gy with a cumulative radiation dose of 60-72 Gy. Planned radiation fields must include at 
least 2 oral sites (left and right buccal mucosa, floor of mouth, left and right lateral tongue, soft 
palate) with each site receiving a cumulative dose of at least 50 Gy.   
Note: Unavoidable doses of at least 50 Gy, to include entrance, exit, and scatter doses, still 
constitute planned radiation. 
3. Patients who have had prior surgery are eligible, provided they have fully recovered from 
surgery, and patients who may have surgery in the future are eligible. 
4. Treatment plan to receive standard cisplatin monotherapy administered either every three weeks 
(100 mg/m2 for 3 doses) or weekly (40 mg/m2 for 6-7 doses). The decision on which cisplatin 
regimen to use in combination with IMRT and GC4419 will be at the discretion of the 
Investigator. 
5. Age 18 years or older 
6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 5 of 73 
7. Adequate hematologic function as indicated by: 
• 
Absolute neutrophil counts (ANC) ≥ 1,500/mm3 
• 
Hemoglobin (Hgb) ≥ 9.0 g/dL 
• 
Platelet count ≥ 100,000/mm3 
8. Adequate renal and liver function as indicated by: 
• 
Serum creatinine acceptable for treatment with cisplatin per institutional guidelines 
• 
Total bilirubin ≤ 1.5  upper-normal limit (ULN) 
• 
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5  ULN 
• 
Alkaline phosphatase ≤ 2.5  ULN 
9. Serum pregnancy test negative for women of childbearing potential 
10. Males and females must agree to use highly effective method of contraception starting prior to 
the first day of treatment and continuing after the last dose of GC4419 for 30 days (females) or 
90 days (males) 
11. Properly obtained written informed consent 
Exclusion Criteria: 
1. Metastatic disease  
2. Prior radiotherapy to the region of the study cancer or adjacent anatomical sites or more than 
25% of total body marrow-bearing area (potentially interfering with chemo-tolerance) 
3. Prior induction chemotherapy or plans for chemotherapy to be administered only sequentially, 
not concurrently, with IMRT 
4. Planned concurrent chemotherapy other than single agent cisplatin 
5. Receiving any approved or investigational anti-cancer agent other than those provided for in this 
study 
6. Concurrent participation in another interventional clinical study or use of another investigational 
agent within 30 days of first dose of GC4419 
Note: Patients who are participating in non-interventional clinical studies (e.g., QOL, imaging, 
observational, follow-up studies, etc.) are eligible, regardless of the timing of participation. 
7. Inability to eat soft solid food at baseline for reasons other than mouth soreness after surgery or 
dental procedures 
8. Complete reliance on parenteral or gastrointestinal tube-delivered nutrition at baseline 
Note: Patients who have gastrostomy tubes prophylactically placed are eligible. Patients 
receiving supplemental nutrition through a gastrostomy tube at baseline may be eligible 
depending on diet. 
9. Malignant tumors other than head and neck cancer (HNC) within the last 5 years, unless treated 
definitively and with low risk of recurrence in the judgment of the treating Investigator 
10. Active infectious disease excluding oral candidiasis 
11. Presence of oral mucositis at baseline. Subjects with mouth or throat pain solely due to post-
operative effects are eligible, however. 
12. Known history of human immunodeficiency virus (HIV) or active hepatitis B/C (patients who 
have been vaccinated for hepatitis B and do not have a history of infection are eligible) 
13. Female patients who are pregnant or breastfeeding 
14. Known allergies or intolerance to cisplatin and similar platinum-containing compounds 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 6 of 73 
15. Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of 
the treating Investigator, create a risk for a precipitous decrease in blood pressure. 
16. Medical history that includes any condition, or requires the use of concomitant medications 
which, in the Investigator’s judgment, are associated with or create a risk of increased carotid 
sinus sensitivity, symptomatic bradycardia, or syncopal episodes. 
Investigational product, dosage and mode of administration: 
GC4419 is formulated as a clear solution at a concentration of 9 mg/mL in 26 mM sodium 
bicarbonate-buffered 0.9 wt. % saline for parenteral administration (drug product). GC4419 will be 
presented in single use vials, one vial per day. Vials will be filled with 11 mL of GC4419, of which 
10 mL be added into a 250 mL bag of normal saline, for daily IV administration over 60 minutes. 
GC4419 will be administered concurrent with daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 
Gy over 7 weeks, plus cisplatin administered 100 mg/m2 once every three weeks for 3 doses or 40 
mg/m2 once weekly for 6-7 doses (Investigator’s choice). 
Duration of treatment: 
Approximately 35 doses, on days in which IMRT is administered, Monday-Friday (M-F), for 
approximately 7 weeks. GC4419 will be administered within 4 hours prior to each IMRT treatment. 
Reference therapy, dosage and mode of administration: 
Not applicable 
Criteria for evaluation: 
Safety: 
National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE), 
version 5.0 
Clinical Laboratory Assessment: A central laboratory vendor will be utilized. 
Efficacy: 
WHO Criteria for OM 
Toxicity Management: 
Toxicity requiring 25% GC4419 dose reduction: 
• 
Grade 2 or greater hypotension within 2 hours after the start of GC4419 infusion 
• 
Grade 3-4 adverse events (AEs) judged by the Investigator to be likely attributable to the 
study infusion. 
Dose reductions of GC4419 should be done in increments of 25% of the starting dose.  Two dose 
reductions for toxicity will be permitted per subject. Subjects unable to tolerate GC4419 after 2 dose 
reductions must discontinue treatment with GC4419 but should continue with cisplatin/IMRT and 
other study assessments and procedures, with the concurrence of the treating Investigator, if the 
subject maintains informed consent to do so. 
For other toxicities (including those attributable to cisplatin and IMRT): management per institutional 
and American Society of Clinical Oncology (ASCO) guidelines and Investigator judgment. Cisplatin 
toxicities should be managed by modification of the cisplatin dose and schedule, not by substitution 
of another systemic agent. 
Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral 
Cavity (ISOO) Oral Care Education Materials and patient instructions for oral hygiene will be 
strongly recommended, and a summary appended to the protocol (Appendix 6). 
OM will NOT be considered an AE requiring dose modification for the purposes of this study. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 7 of 73 
Concomitant Medications/Treatments: 
Investigators may prescribe concomitant medication or supportive therapy deemed necessary to 
provide adequate supportive care for complications other than OM, e.g., antiemetics, systemic 
antibiotics, hydration to prevent renal damage, etc. 
Hematopoietic growth factor use is permitted per ASCO guidelines. Following ASCO (and MASCC) 
guidelines for the prevention and management of chemotherapy-induced nausea and vomiting 
(CINV) is strongly encouraged. 
Oral care per MASCC/ISOO Oral Care Education Materials (summarized in Appendix 6) is strongly 
recommended for all subjects as part of standard of care.   
Oral topical lidocaine is permitted. 
Diphenhydramine (Benadryl®) administered as tablets or by injection is permitted. 
The following must not be used: 
• 
Nitrates, phosphodiesterase type 5 (PDE 5) inhibitors (e.g., sildenafil, tadalafil, or similar 
agents) or other drugs that in the judgment of the treating Investigator could create a risk of a 
precipitous decrease in blood pressure are prohibited until at least 24 hours after the last dose 
of GC4419 
• 
Pyridostigmine or other drugs that in the judgment of the treating Investigator could create a 
risk of increased carotid sinus sensitivity, symptomatic bradycardia, or syncopal episodes. 
• 
Palifermin (Kepivance®) or another keratinocyte or fibroblast growth factor 
• 
Amifostine (Ethyol®) 
• 
Benzydamine (Difflam®, Pharixia®, Tantum Verde) 
• 
Low-level laser treatment  
• 
Glutamine applied topically 
• 
GM-CSF applied topically 
• 
‘Mouthwashes’ that include the following:  
o Chlorhexidine 
o Hydrogen peroxide 
o Diphenhydramine (Benadryl®) liquid formulation 
o Tetracycline 
o Any other listed disallowed medications 
• 
MuGard™, Gelclair®, Episil®, or other barrier devices 
• 
Caphosol® 
• 
Povidone-iodine rinses 
• 
Steroid rinses 
• 
Sucralfate in suspension form (use of sucralfate tablets is not proscribed) 
• 
Biologic response modifiers – except systemic hematopoietic growth factors for the 
management of anemia or myelosuppression 
• 
Concurrent approved or investigational anti-cancer therapy (e.g., chemotherapy, 
immunotherapy, targeted therapy, hormone and biologic therapy) other than the Protocol 
regimen 
• 
Other investigational agents 
All medication restrictions end after IMRT is completed unless otherwise noted. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 8 of 73 
Statistical methods: 
The primary objective of this study is to further assess the safety profile of GC4419, with efficacy 
objectives of cumulative incidence of SOM, days of SOM, and tumor outcome key secondary 
efficacy endpoints. No formal statistical hypothesis testing is prespecified for the primary safety 
objectives. A sample size of up to 70 subjects has been selected to obtain adequate safety and efficacy 
subject data to compare with observed data in North American studies and historical controls for 
IMRT with Cisplatin. These results will also contribute to pooled analysis of an overall minimum 
safety database of 300 subjects with head and neck cancer who will, across all studies of GC4419, 
have received a full course of GC4419 at the intended dose (90 mg), schedule (1-hour infusion, 5 
days/week, prior to IMRT), and duration (single course of 6-7 weeks) in combination with concurrent 
IMRT and cisplatin.  The overall safety database size of 300 will allow for detection with 95% 
probability of adverse events of 1% true incidence in at least 1 subject.   
As this is the first study of this drug in EU, the efficacy analysis will allow for comparison to North 
American results and historical controls and confirm uniformity in applying OM scoring procedures 
used for WHO criteria that could be used to inform future development programs. 
Safety and efficacy will be assessed on an “intent to treat” (ITT) population consisting of all enrolled 
subjects who receive at least one dose of GC4419, and on a "per protocol" population consisting of 
subjects who receive at least 60 Gy of IMRT and at least 5 weeks (25 doses) of GC4419. Overall 
rates of adverse events, serious adverse events, and SOM/Grade 4 OM incidence will be summarized 
descriptively.  

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 9 of 73 
2. 
TABLE OF CONTENTS 
1. 
SYNOPSIS ...............................................................................................................................3 
2. 
TABLE OF CONTENTS .........................................................................................................9 
3. 
GLOSSARY ...........................................................................................................................13 
4. 
INTRODUCTION ..................................................................................................................15 
4.1. 
Background ........................................................................................................................15 
4.1.1. 
Oral Mucositis in Patients Treated with Chemoradiation for HNC .............................15 
4.1.2. 
Oral Mucositis is an Unmet Medical Need ..................................................................16 
4.2. 
GC4419 Overview .............................................................................................................17 
5. 
STUDY OBJECTIVES, ENDPOINTS AND PURPOSE ......................................................20 
5.1. 
Objectives ..........................................................................................................................20 
5.2. 
Endpoints ...........................................................................................................................20 
5.2.1. 
Rationale for WHO Scale of OM (Secondary Endpoints) ...........................................20 
6. 
INVESTIGATIONAL PLAN .................................................................................................22 
6.1. 
Overall Study Design .........................................................................................................22 
6.2. 
Treatment Plan and Duration of Therapy ..........................................................................22 
6.2.1. 
Rationale for GC4419 Dose and Schedule Selection ..................................................23 
6.2.2. 
Rationale for Cisplatin/IMRT Treatment Plan ............................................................23 
7. 
SELECTION AND WITHDRAWAL OF SUBJECTS ..........................................................25 
7.1. 
Subject Inclusion Criteria ..................................................................................................25 
7.2. 
Subject Exclusion Criteria .................................................................................................26 
7.3. 
Rationale for Patient Population ........................................................................................26 
7.4. 
Screen Failures ...................................................................................................................27 
7.5. 
Randomization Failures .....................................................................................................27 
7.6. 
Subject Withdrawal Criteria ..............................................................................................27 
7.7. 
Study and Site Closure .......................................................................................................28 
8. 
GC4419 ...................................................................................................................................29 
8.1. 
Description of GC4419 ......................................................................................................29 
8.1.1. 
GC4419 ........................................................................................................................29 
8.2. 
Treatment Assignment .......................................................................................................29 
8.3. 
GC4419 Packaging and Labeling ......................................................................................29 
8.4. 
GC4419 Storage .................................................................................................................29 
8.5. 
GC4419 Preparation...........................................................................................................30 
8.6. 
GC4419 Administration .....................................................................................................30 
8.7. 
GC4419 Accountability and Compliance ..........................................................................33 
8.8. 
GC4419 Handling and Disposal ........................................................................................33 
8.9. 
Concomitant Medications ..................................................................................................33 
8.9.1. 
Prohibited Medications ................................................................................................34 
9. 
TOXICITY MANAGEMENT ................................................................................................36 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 10 of 73 
9.1. 
Dose Delays and Dose Modifications for Toxicity............................................................36 
9.2. 
Supportive Care Guidelines ...............................................................................................36 
9.2.1. 
Supportive care for chemotherapy-induced nausea and vomiting (CINV) .................36 
10. ASSESSMENTS.....................................................................................................................37 
10.1. Safety Assessments ............................................................................................................37 
10.1.1. 
Clinical Assessments ...................................................................................................37 
10.1.2. 
Laboratory Assessments ..............................................................................................37 
10.2. Symptom Related Questionnaires ......................................................................................38 
10.3. Oral Mucositis Assessments ..............................................................................................38 
10.4. Radiation Therapy Quality Assurance ...............................................................................39 
10.5. Pharmacokinetic (PK) Measurements of GC4419 .............................................................39 
10.6. Tumor Status Assessment ..................................................................................................40 
10.6.1. 
Tumor Imaging ............................................................................................................40 
10.6.1.1. 
Pre-Treatment Tumor Imaging ..............................................................................40 
10.7. Schedule of Time and Events ............................................................................................40 
10.7.1. 
Screening......................................................................................................................40 
10.7.2. 
Treatment Phase ...........................................................................................................41 
10.7.2.1. 
Prior to GC4419 Infusion.......................................................................................41 
10.7.2.2. 
GC4419 Infusion ....................................................................................................42 
10.7.2.3. 
Following GC4419 Infusion ..................................................................................43 
10.7.3. 
Follow-up Phase...........................................................................................................43 
10.7.3.1. 
Post-IMRT OM Follow Up ....................................................................................43 
11. ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS ..............................................44 
11.1. Definitions..........................................................................................................................44 
11.1.1. 
Adverse Event (AE) .....................................................................................................44 
11.1.2. 
Serious Adverse Event (SAE) ......................................................................................44 
11.2. Adverse Event Reporting Requirements ............................................................................45 
11.2.1. 
Serious Adverse Events ...............................................................................................45 
11.2.2. 
Collection Period for AEs and SAEs ...........................................................................45 
11.2.3. 
Clinical Laboratory Abnormalities and Other Abnormal Assessments as AEs 
and SAEs ....................................................................................................................46 
11.2.4. 
Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as 
AEs or SAEs ...............................................................................................................46 
11.2.5. 
Grading of Adverse Events ..........................................................................................46 
11.3. Relationship to Study Drug ................................................................................................47 
11.4. Recording Adverse Events .................................................................................................48 
11.5. Follow-up of AEs and SAEs ..............................................................................................48 
11.6. Post-Study Reporting Requirements ..................................................................................49 
11.7. Regulatory Reporting of Adverse Events ..........................................................................49 
11.8. Pregnancy ...........................................................................................................................49 
11.8.1. 
Time Period for Collecting Pregnancy Information ....................................................50 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 11 of 73 
11.8.2. 
Action to be Taken if Pregnancy Occurs in a Female Partner of a Male Subject........51 
12. STATISTICS ..........................................................................................................................52 
12.1. General Considerations ......................................................................................................52 
12.1.1. 
Randomization and Stratification ................................................................................52 
12.2. Sample Size ........................................................................................................................52 
12.3. Analysis Populations ..........................................................................................................52 
12.4. Safety Analysis ..................................................................................................................52 
12.5. Efficacy Analysis ...............................................................................................................53 
12.5.1. 
Multiplicity ..................................................................................................................53 
12.5.2. 
Handling of Missing Data ............................................................................................53 
12.5.3. 
Covariate Adjustment ..................................................................................................53 
12.6. Exploratory Analyses .........................................................................................................53 
12.7. ETHICS..............................................................................................................................53 
12.7.1. 
Ethical Conduct of the Study .......................................................................................53 
12.7.2. 
Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC)/Research Ethics Board (REB) Approval ..........................................................53 
12.8. Written Informed Consent .................................................................................................54 
12.9. Data Monitoring Committee (DMC) .................................................................................54 
13. DIRECT ACCESS TO SOURCE DATA/DOCUMENTS.....................................................55 
13.1. Study Monitoring ...............................................................................................................55 
13.2. Audits and Inspections .......................................................................................................55 
13.3. Protocol Compliance ..........................................................................................................55 
13.4. Protocol Modifications.......................................................................................................56 
13.5. Information Disclosure ......................................................................................................56 
13.5.1. 
Ownership ....................................................................................................................56 
13.5.2. 
Confidentiality .............................................................................................................56 
13.5.3. 
Publication ...................................................................................................................56 
14. QUALITY CONTROL AND QUALITY ASSURANCE .....................................................57 
15. DATA HANDLING AND RECORDKEEPING ...................................................................58 
15.1. Case Report Forms .............................................................................................................58 
15.2. Retention/Inspection of Records ........................................................................................58 
16. LIST OF REFERENCES ........................................................................................................59 
APPENDIX 1. .................................................................................................................. SCHEDULE OF 
ASSESSMENTS.....................................................................................................................64 
APPENDIX 2. .......................... WORLD HEALTH ORGANIZATION (WHO) SCORE OF ORAL 
MUCOSIT`IS .........................................................................................................................67 
APPENDIX 3. ..............................................................................................PERFORMANCE STATUS 
CONVERSION.......................................................................................................................68 
APPENDIX 4. ... NATIONAL CANCER INSTITUTE-COMMON TERMINOLOGY CRITERIA 
FOR ADVERSE EVENTS, VERSION 5.0 ...........................................................................69 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 12 of 73 
APPENDIX 5. ............... RECOMMENDED REGIMENS FOR HIGH-RISK CHEMOTHERAPY-
INDUCED NAUSEA AND VOMITING (CINV) PER ASCO AND MASCC 
GUIDELINES .........................................................................................................................70 
APPENDIX 6. ........................................................................................................ DAILY ORAL CARE 
RECOMMENDATIONS ........................................................................................................72 
APPENDIX 7. ..................................................................................................... SYMPTOM RELATED 
QUESTIONNAIRE ................................................................................................................73 
 
LIST OF TABLES 
Table 1: 
Abbreviations and Specialist Terms ......................................................................13 
Table 2: 
Chemoradiation and GC4419 Administration Schedule  Example: 35 Doses of 
GC4419 (5 days/week over 7 Week Schedule) .....................................................31 
Table 3: 
Pharmacokinetic Sampling Schedule to Assess GC4419 ......................................40 
Table 4: 
Adverse Event Severity..........................................................................................47 
Table 5: 
Schedule of Assessments .......................................................................................64 
Table 6: 
Antiemetic Dosing for Adults – High Risk (Cisplatin) .........................................70 
 
 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 13 of 73 
3. 
GLOSSARY 
The following abbreviations and specialist terms are used in this study protocol. 
Table 1: 
Abbreviations and Specialist Terms 
Abbreviation or Specialist Term 
Definition 
AE 
Adverse Event 
AJCC 
American Joint Committee on Cancer 
ALT 
Alanine Aminotransferase 
ANC 
Absolute Neutrophil Count 
ASCO 
American Society of Clinical Oncology 
AST 
Aspartate Aminotransferase 
BSA 
Body Surface Area 
BUN 
Blood Urea Nitrogen 
CFR 
Code of Federal Regulation 
CINV 
Chemotherapy-Induced Nausea and Vomiting 
CRF 
Case Report Form 
CRT 
Chemo-Radiotherapy  
CS 
Clinically Significant 
CTCAE 
Common Terminology Criteria for Adverse Events 
DMC 
Data Monitoring Committee 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
FDA 
Federal Drug Administration 
GCP 
Good Clinical Practice 
Gy 
Gray 
Hgb 
Hemoglobin 
HIV 
Human Immunodeficiency Virus 
HNC 
Head and Neck Cancer 
HPV 
Human Papilloma Virus 
HSCT 
Hematopoietic Stem Cell Transplantation 
ICF 
Informed Consent Form 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 14 of 73 
Abbreviation or Specialist Term 
Definition 
IMRT 
Intensity-Modulated Radiation Therapy 
IND 
Investigational New Drug 
IRB 
Institutional Review Board 
ISOO 
International Society of Oral Oncology 
ITT 
Intent-to-Treat 
IV 
Intravenous 
IXRS 
Interactive Voice and Web Response System 
MASCC 
Multinational Association of Supportive Care in Cancer 
M-F 
Monday to Friday 
MnSOD 
Manganese Superoxide Dismutase  
NCI 
National Cancer Institute 
NCS 
Non-Clinically Significant 
NEPA 
Netupitant-palonosetron 
OC 
Oral Cavity 
OM 
Oral Mucositis 
OP 
Oropharynx 
PK 
Pharmacokinetic 
QOL 
Quality of Life 
REB 
Research Ethics Board 
ROS 
Reactive Oxygen Species 
RT 
Radiation Therapy 
SAE 
Serious Adverse Event 
SAS 
Statistical Analysis System 
SCC 
Squamous Cell Carcinoma 
SCCHN 
Squamous Cell Carcinoma of the Head and Neck 
SOD 
Superoxide Dismutase 
SOM 
Severe Oral Mucositis 
SUSAR 
Suspected Unexpected Serious Adverse Reaction 
TCD 
Tumor cure dose 
ULN 
Upper Limit of Normal 
WHO 
World Health Organization 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 15 of 73 
4. 
INTRODUCTION 
4.1. 
Background 
4.1.1. 
Oral Mucositis in Patients Treated with Chemoradiation for HNC 
Oral mucositis (OM) is a common, problematic, and painful complication of cancer therapy, 
particularly in regimens that include radiation to the head and neck (Sonis 2009). Oral mucositis 
is readily graded using the commonly-used five-point World Health Organization (WHO) scale 
(Appendix 2). 
Most patients receiving combined chemoradiotherapy for head and neck cancer (HNC) can be 
expected to develop severe (WHO Grade 3-4) OM (SOM) (Sonis, Elting et al. 2004), and nearly 
all HNC patients receiving radiation therapy (RT) with concurrent cisplatin are expected to 
develop ulcerative OM (WHO Grade 2 or higher) (Traynor, Richards et al. 2010). The 
consequences for patients developing SOM are especially serious, because, by definition, Grade 
3-4 OM entails compromise to nutrition and/or hydration, and may require surgical procedure, 
RT interruption, and/or hospitalization. 
Standard chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck 
(SCCHN), whether in the post-operative or definitive setting, currently consists of intensity-
modulated radiation therapy (IMRT) plus systemic therapy. Common systemic treatment is with 
single-agent cisplatin, administered either q3 weeks or once weekly schedule (Mendenhall, 
Amdur et al. 2006; Salama, Seiwert et al. 2007; Ang, Zhang et al. 2014; Nguyen-Tan, Zhang et 
al. 2014). The monoclonal antibody cetuximab has also been shown to increase the efficacy of 
radiotherapy for locally advanced head and neck cancer (Bonner, Harari et al. 2006). However, 
recently reported results from the RTOG 1016 study in human papilloma virus (HPV)-associated 
oropharyngeal cancer showed survival after IMRT plus cetuximab to be inferior to that obtained 
with IMRT/cisplatin (Trotti, et al. 2018).   
Published observations for patients treated with RT for HNC, without additional treatment to 
prevent OM, indicate that approximately 50% of patients receiving RT alone (Bonner, Harari et 
al, 2006), and that approximately 70% of patients receiving RT plus single-agent cisplatin may 
be expected to develop SOM, with a median duration of approximately 3-4 weeks among those 
who develop SOM, a median time to onset of approximately 28-35 days after the start of therapy, 
and a cumulative incidence of approximately 10% per week/10 Gy. Data for the placebo groups 
in two published Phase 3 studies of Kepivance® (palifermin) in patients receiving RT plus 
single-agent cisplatin for SCCHN (Henke, Alfonsi et al. 2011; Le, Kim et al. 2011), and results 
for patients receiving IMRT plus platinum plus placebo in a more recent report (Kudrimoti, 
Curtis et al. 2016) support these observations. Adding cetuximab to standard chemoradiation 
regimens for HNC increases the risk of significant OM (Ang, Zhang et al. 2014).  
Among patients being treated for HNC, OM follows a predictable and well-documented course 
(Sonis 2011). By the end of the first week of treatment (typically cumulative radiation doses of 
10 Gy), erythema of the oral mucosa is usually seen, and patients complain of discomfort that is 
characterized as burning. This relatively mild pain escalates between the second and third week 
of treatment (radiation doses of 20 Gy to 30 Gy), when frank ulceration of the mucosa develops. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 16 of 73 
Lesions at this stage often necessitate a modification in food intake and a marked increase in the 
need for analgesics. Individual ulcers frequently coalesce as radiation progresses resulting in 
confluent injury affecting many aspects of the oral mucosa. Pain intensifies and may be 
inadequately controlled even with aggressive narcotic therapy (Elting, Cooksley et al. 2007). 
OM has substantial impact on day-to-day functioning. In addition to the common need for, and 
inadequate pain control with, narcotics, the profound clinical impact of OM also includes weight 
loss, difficulty eating and swallowing, dehydration, need for nutritional support, and reduced 
performance status (Elting, Cooksley et al. 2007), as well as secondary infections at sites of 
ulcerative OM (Bodey, Rodriguez et al. 1978), and diminished quality of life (QOL) outcomes 
(Elting, Keefe et al. 2008). Patients with HNC may also suffer the additional complications of 
short- and long-term xerostomia, taste change, and trismus related to post-radiation fibrosis. 
These consequences are particularly pronounced in patients manifesting severe OM, and 
especially in the 20-30% who suffer Grade 4 and require artificial alimentation, usually via a 
percutaneous gastrostomy tube. 
Among patients treated for HNC, even mild mucositis results in more frequent hospitalization 
and breaks in treatment, introducing the risk of compromised anti-tumor efficacy (Vera-Llonch, 
Oster et al. 2006; Russo, Haddad et al. 2008). In granulocytopenic patients, mucositis is strongly 
associated with an increased risk of bacteremia and sepsis (Ruescher, Sodeifi et al. 1998). 
Adverse health economic outcomes include increased analgesic and antibiotic use, increased 
number of febrile days, need for parenteral nutrition, prolonged length of hospital stay, and 
increased resource use and associated cost (Nonzee, Dandade et al. 2008). 
4.1.2. 
Oral Mucositis is an Unmet Medical Need 
Oral mucositis prevention and management remains a substantial unmet need. For years, there 
has been no substantial change in its management (Keefe 2006). Current guidelines (Lalla, 
Bowen et al. 2014) from the Multinational Association of Supportive Care in Cancer and the 
International Society of Oral Oncology (MASCC/ISOO) limit recommended or suggested 
interventions to prevent OM to: 
• Kepivance® (palifermin) in the setting of high-dose chemotherapy and total body 
irradiation, followed by autologous hematopoietic stem cell transplantation (HSCT), for a 
hematological malignancy. However, Kepivance® is not licensed/approved for the 
treatment of OM associated with HNC; 
• Oral cryotherapy in the setting of 5-fluorouracil therapy or chemotherapy/HSCT; 
• Low-level laser therapy in the setting of chemotherapy/HSCT or chemoradiotherapy for 
HNC; 
• Benzydamine mouthwash in the setting of HNC treated with moderate-dose RT, without 
concomitant chemotherapy; 
• Oral zinc supplements in the setting of radiation or chemoradiation; 
• Oral care protocols across all cancer treatment modalities. 
Narcotics and doxepin mouthwash are recommended or suggested by MASCC/ISOO for the 
treatment of OM-related pain. Several other agents currently used to treat OM symptoms, while 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 17 of 73 
designed to palliate associated pain or manage infection, do not alter the underlying biologic 
processes that give rise to OM. MASCC/ISOO currently recommends or suggests against the use 
of some agents that have historically been used (e.g., antimicrobial mouthwashes, sucralfate, 
chlorhexidine mouthwash), citing evidence for lack of effectiveness against OM in one or more 
treatment settings. 
Further, no approved product is available in the US (or elsewhere) for OM in the vast majority of 
these patients, especially those with solid tumors such as SCCHN. At present, palifermin is the 
only FDA-approved (licensed) product for OM but its indicated use (patients receiving HSCT for 
hematologic malignancies) is limited to a very small cohort (4%) of the total population at risk 
for OM: a cohort associated with conditioning regimens prior to stem cell transplant for the 
treatment of hematologic malignancies. The approval specifically excludes patients with solid 
tumors (Spielberger, Stiff et al. 2004). 
A few medical devices are on the market, but they generally lack sufficient data to allow 
recommendation. The mucoadhesive MuGard™ is indicated as a palliative treatment for the 
management of OM but requires administration 4 to 6 times per day for optimal effect and does 
not alter the mechanism of OM (MuGard prescribing information). The oral gel Gelclair® has a 
similar use and effect for OM or oral irritation due to other causes but does not affect the 
mechanism of OM. Caphosol® (supersaturated calcium phosphate rinse) is indicated for 
xerostomia or as an adjunct to standard oral care for OM but failed to reduce the incidence of 
ulcerative or severe OM in a recently-published Phase 2 study (Rao, Trotti et al. 2014). The 
lipid-based oral barrier rinse Episil® and the bacteriostatic rinse GelX® (zinc gluconate-taurine 
complex) may be used for pain related to OM but do not affect the mechanism causing OM. 
Therefore, current standard of care for patients with solid tumors consists of oral care protocols 
and palliative approaches to deal with painful symptoms. An urgent need remains for novel 
products, like GC4419, aimed at reducing the incidence and severity of severe OM. 
4.2. 
GC4419 Overview 
GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a 
molecular weight of 483 g/mol, whose activity mimics that of naturally occurring superoxide 
dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective 
SOD mimetics. GC4419 selectively removes superoxide (O2•-) without reacting with other 
reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite. In 
addition, unlike native SOD, GC4419 is not deactivated by nitration. 
GC4419 is being developed for the initial indication of reduction of the incidence and severity of 
severe OM induced by RT, with or without systemic therapy, under IND 111,539 with the 
Division of Dermatology and Dental Products (DDDP), United States FDA. 
By efficiently and rapidly removing O2•- , GC4419 offers a treatment paradigm for preventing 
or controlling OM. Numerous published studies indicate that OM, esophagitis, pneumonitis, 
fibrosis, or other normal-tissue radiation damage may be reduced by treatment with liposomally 
encapsulated exogenous manganese (Mn) SOD or a MnSOD transgene, exogenous Cu/Zn SOD, 
or a dismutase mimetic enantiomerically related to GC4419 (Delanian, Baillet et al. 1994; 
Epperly, Defilippi et al. 2000; Guo, Seixas-Silva et al. 2003; Murphy, Fey et al. 2008; 
Thompson, Chu et al. 2010). 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 18 of 73 
GC4419 was studied extensively in nonclinical settings, in different animal models, and various 
human xenograft and murine syngeneic tumor models (for details see the Investigator’s 
Brochure). Nonclinical data have identified GC4419 as a promising new radioprotective, anti-
cancer and anti-inflammatory agent. GC4419 was active as a radio-protectant in animal models 
of cancer radiation therapy and added to the activity of chemotherapeutic agents in animal 
models of cancer. Importantly, GC4419 did not interfere with the anti-tumor effects of either 
radiation therapy or chemotherapy in animal models of cancer. 
GC4419 was studied in a Phase 1b/2a clinical study, GT-001 (NCT01921426, 
Anderson, Sonis, et al. 2018) and Phase 2b study, GT-201 (NCT02508389). In study GT-001, 
GC4419 was administered throughout the full 6- to 7-week course of chemo-radiotherapy (CRT) 
at doses of either 30 or 90 mg, Monday-Friday (M-F), and appeared to substantially reduce the 
duration, incidence, and overall severity (defined here as the incidence specifically of Grade 4) 
of severe OM compared with historical expectations (data are based on 43 evaluable subjects). 
Further, GC4419 did not appear to increase the known toxicity of the CRT regimen (IMRT plus 
concurrent cisplatin), nor did it appear to interfere with tumor response to CRT assessed through 
1 year post therapy (for details see Anderson, Sonis, et al. 2018 and the Investigator's Brochure). 
These results supported the design of the randomized, double-blind, placebo-controlled, Phase 2b 
study GT-201, with two GC4419 doses of 30 and 90 mg selected for comparison with placebo 
and administered 5 days/week. As in GT-001, patients eligible for GT-201 were required to have 
locally advanced squamous cell carcinoma of the oral cavity (OC) or oropharynx (OP), with their 
standard care calling for concurrent IMRT and cisplatin. Results from 223 randomized subjects 
indicated that GC4419 at daily dose of 90 mg resulted in statistically significant reduction on the 
primary endpoint, severe OM duration, for subjects on the 90 mg arm compared to placebo, as 
determined by the non-parametric Van Elteren test.  The median duration of SOM, as defined in 
the protocol, was 1.5 days for subjects receiving 90 mg of GC4419 vs 19 days for subjects 
receiving placebo (p=0.024).  Also, the incidence of SOM during the IMRT treatment period was 
43% for subjects receiving 90 mg of GC4419 vs 65% for subjects receiving placebo (nominal p 
value=0.009), a relative reduction of approximately 34%. The safety profile of GC4419 in 
combination with the IMRT/platinum regimen in GT-201 study was acceptable; safety results 
with both the 90 mg dose and the 30 mg dose were similar to those with placebo (Anderson et al, 
2019).  Two year follow up for standard tumor outcomes (progression-free survival, overall 
survival, local control, distant metastasis-free rate) did not vary among the three study arms 
(Anderson et al, 2020). 
Based on these results, a randomized, double-blind, placebo-controlled Phase 3 trial, GTI-4419-
301, has been initiated in the US and Canada.  This study is of substantially the same design as 
GT-201, and is limited to patients with tumors of the oral cavity and oropharynx, as was the case 
in GT-001 and GT-201.  GTI-4419-301 is a 2-arm study, with eligible subjects randomized in a 
3:2 ratio to 90 mg of GC4419 or placebo in combination with IMRT/cisplatin.  In accordance 
with discussions with regulatory authorities, the primary endpoint of GTI-4419-301 is the 
incidence of SOM during the study treatment period (through the last fraction of IMRT). 
Secondary efficacy endpoints are incidence of Grade 4 OM through the study treatment period, 
and the number of days of SOM or Grade 4 OM, defined as was "duration" of SOM in GT-201. 
The sample size is 335 randomized subjects who receive at least one dose of GC4419 or placebo. 
However, additional data will be needed to permit assessment of the safety of GC4419 at the 
intended dose, schedule, and duration of administration, in combination with IMRT/cisplatin, to 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 19 of 73 
identify adverse events with an overall frequency of approximately 1%.  The present study will 
obtain these data along with further exploratory information about the incidence of SOM in 
patients receiving 4419 plus IMRT/cisplatin for a range of head and neck cancers. 
Additional details about the pathogenesis of OM, the mechanism of action of GC4419, and the 
results of non-clinical testing as well as the clinical trials GT-001 and GT-201 are provided in the 
Investigator's Brochure.  

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 20 of 73 
5. 
STUDY OBJECTIVES, ENDPOINTS AND PURPOSE 
5.1. 
Objectives 
Primary Objective: 
• To assess the safety of GC4419 administered intravenously (IV) to subjects receiving 
post-operative or definitive therapy with single-agent cisplatin plus Intensity-Modulated 
Radiation Therapy (IMRT) for locally advanced, non-metastatic squamous cell 
carcinoma (SCC) of the head and neck 
Secondary Objective: 
• To assess the incidence of severe oral mucositis (SOM; World Health Organization 
Grade 3 or 4) in the study population  
5.2. 
Endpoints 
Primary Endpoint: 
• Frequency, duration, and severity of AEs and serious AEs (SAEs); 
• Incidence and shifts of clinically significant laboratory abnormalities 
Secondary Endpoints: 
• Cumulative incidence of SOM, defined as any occurrence of WHO Grade 3-4 OM, from 
the first IMRT fraction through the end of the study treatment period (last day of IMRT) 
• Cumulative incidence of WHO Grade 4 OM and days of Grade 4 OM from the first 
IMRT fraction through the end of the study treatment period (last day of IMRT) 
• Cumulative incidence of SOM, and days of SOM, from the first IMRT fraction through 
two weeks after the end of IMRT. 
5.2.1. 
Rationale for WHO Scale of OM (Secondary Endpoints) 
The WHO scale is commonly used to assess OM in clinical care and research settings. Originally 
developed as a standard toxicity reporting index, it has evolved into the most accepted outcome 
for efficacy testing of drugs as it has been shown to meet key characteristics for clinical studies: 
• Accurate reflection of the severity and course of the objective and subjective changes of 
mucositis. 
• Easy to teach with a low inter-observer variability. 
• Does not require measurement of lesions. 
• Sensitive enough to discriminate treatment efficacy. 
• Clinically meaningful and easily interpreted endpoints for clinicians, patients and 
regulatory agencies. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 21 of 73 
The WHO scale has been used as the primary efficacy endpoint for many studies and is accepted 
internationally.  There is also precedent for using severe OM as defined by the WHO scale as the 
basis for drug approval specifically in the case of palifermin.  
Because of the nature of the WHO grading scale (see Appendix 2), improvement of SOM (WHO 
Grade 3-4) of meaningful magnitude implies clinical benefit.  

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 22 of 73 
6. 
INVESTIGATIONAL PLAN 
6.1. 
Overall Study Design 
GTI-4419-202 is an open-label, multi-center international study conducted to evaluate the effects 
of GC4419 when administered IV in combination with IMRT/cisplatin to subjects with head and 
neck cancer, who are at high risk for SOM. 
6.2. 
Treatment Plan and Duration of Therapy 
Subjects will receive 90 mg GC4419 per day (60 min IV infusion to complete within four hours 
prior to IMRT), concurrent with daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over 
approximately 7 weeks, plus cisplatin administered 100 mg/m2 once every three weeks for 3 
doses or 40 mg/m2 once weekly for 6-7 doses (Investigator’s choice) 
Note: Planned radiation fields must include at least 2 oral sites (left and right buccal mucosa, 
floor of mouth, left and right lateral tongue, soft palate) that each receive a cumulative dose of at 
least 50 Gy. 
GC4419 will be given IV by a 60-minute infusion. IMRT must be initiated as soon as possible 
upon completion of the GC4419 infusion but no later than four hours following the end of the 
GC4419 infusion. 
GC4419 will be given beginning on the first day of radiation and continuing daily, concurrent 
with each dose of IMRT, to a cumulative radiation dose of approximately 60-72 Gy. 
If IMRT is not administered on any given day due to a treatment break or unforeseen 
circumstances, GC4419 should not be administered on that day. Breaks in IMRT will be 
determined by the subject’s treating physician in accordance with standard of care. Subjects 
should resume GC4419 administration when IMRT resumes. On days when planned doses of 
both GC4419 and IMRT are not administered (e.g., due to a holiday site closure, etc.), GC4419 
dosing may be extended along with IMRT to make up any missed dose up to a maximum of 35 
doses of GC4419. If a fraction of IMRT is not administered for any reason after GC4419 has 
been administered, that day’s GC4419 will count as one of the 35 doses. 
Anti-emetic prophylaxis and hematopoietic growth factor use should be administered per 
American Society of Clinical Oncology (ASCO) guidelines (Appendix 5). If institutional 
guidelines permit, cisplatin may be administered prior to or after the first day of IMRT, as long 
as it follows a weekly or tri-weekly schedule. On days in which chemotherapy and GC4419 are 
administered, the following administration sequence should be used when possible to ensure that 
IMRT is initiated within four hours of the stop time of GC4419 infusion: GC4419, IMRT, 
prehydration, and cisplatin. Patients treated with induction chemotherapy prior to concomitant 
chemoradiation are not eligible for this study. 
All subjects will be assessed twice weekly for oral mucositis per WHO grading criteria until the 
end of the study treatment period (last day of IMRT).  
Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral 
Cavity (ISOO) Oral Care Education Materials and patient instructions for oral hygiene should be 
strongly recommended.  A summary of those guidelines and instructions is appended to the 
protocol (Appendix 6). 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 23 of 73 
6.2.1. 
Rationale for GC4419 Dose and Schedule Selection 
The GC4419 dose (90 mg), route (IV), infusion duration (60 minutes), schedule (weekdays prior 
to IMRT) and treatment duration (6-7 weeks) for this study are those that are being studied in the 
Phase 3 trial of GC4419 and that are intended for eventual clinical use.  Data from the Phase 2 
GT-201 study indicate that the acute toxicity of GC4419 and the overall adverse event profile in 
combination with IMRT/cisplatin are acceptable and as expected. Safety results with 90 mg dose 
were similar to those with Placebo and GC4419 does not appear to increase the toxicity of 
IMRT/cisplatin. In addition, the 90 mg dose of GC4419 in study GT-201 met its primary 
endpoint versus Placebo in demonstrating reduced duration of severe OM, and with strong 
statistical significance (p=0.024). Also, of note is that Phase 2 data have indicated an apparent 
dose response between the 90 mg, 30 mg, and Placebo arms.   
6.2.2. 
Rationale for Cisplatin/IMRT Treatment Plan 
Meta-analyses have indicated superior survival for HNC patients treated with concurrent 
chemoradiotherapy compared with standard fractionation (M-F) radiation therapy alone. While 
not all available regimens have been tested directly against one another, the benefit appears 
superior for single-agent cisplatin over other chemotherapy regimens (Pignon, le Maitre et al. 
2009). Further, recently reported results from the RTOG 1016 study in human papilloma virus 
(HPV)-associated oropharyngeal cancer showed survival after IMRT plus cetuximab to be 
inferior to that obtained with IMRT/cisplatin (Trotti, et al. 2018).  Accordingly, in the current 
study, the still-standard cisplatin/IMRT regimen has been chosen as it poses a significant medical 
need by virtue of the predictable and high incidence of associated severe OM. 
Standard fractionation (five fractions/week, delivered M-F) IMRT has been chosen for the 
current study. Although accelerated fractionation (six fractions/week, combined with two rather 
than three doses of cisplatin q3 weeks), has been studied, prospective lead investigators have 
advised that standard fractionation remains the widely-used standard, and in the interest of using 
a chemoradiation regimen that is as uniform and commonly-used as possible, the standard 
fractionation approach is being retained. Accelerated fractionation appears to increase the 
incidence of severe OM (Overgaard, Hansen et al. 2003). 
In the event that a radiation fraction is missed because of a holiday or technical issues, 
administering two fractions in a subsequent day, to maintain five fractions per week, will be 
allowed, at the discretion of the treating investigator and consistent with institutional practice. 
Cisplatin is administered concomitantly with IMRT by either a q3weekly or weekly schedule.  
Recent literature reviews (Sturtz, Wouters et al. 2017; Jacinto, Co, et al. 2017) have found no 
differences in tumor outcomes or mucositis between the two schedules.  A randomized trial in 
the adjuvant (post-operative) setting (Noronha, Joshi, et al. 2018), in which 87% of patients 
enrolled had squamous cancer of the oral cavity, cited superior progression-free survival for the 
q3weekly arm, with no difference in mucositis.  However, the weekly dose of cisplatin in that 
study was 30 mg/m2.  Other reports (Stojan, Vermorken et al. 2015; Nguyen-Tan, Zhang et al. 
2014) have described a relationship between total cisplatin dose and overall survival in 
combination with RT for HNC, with a target cumulative cisplatin dose of 200 mg/m2 or greater 
now appearing indicated as standard of care to obtain improved survival with RT/cisplatin over 
RT alone.  This threshold could be missed with weekly cisplatin doses < 40 mg/m2.  In the 
present trial, cisplatin doses of 100 mg/m2 by the q3week schedule, and 40 mg/m2 by the weekly 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 24 of 73 
schedule, will be required.  The risk of severe OM may not be different according to cisplatin 
schedule, and no such difference was demonstrated in a subset analysis from GT-201 (data not 
shown). Either regimen will be accepted as within the IMRT/cisplatin standard of care for the 
patient population to be enrolled in the present study.   

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 25 of 73 
7. 
SELECTION AND WITHDRAWAL OF SUBJECTS 
Up to 70 subjects will be enrolled to ensure that the required number of subjects for program 
need receive a full (5+ weeks) course of GC4419, with an assumed proportion of early 
discontinuations, for any reason, of approximately 10-20%. 
7.1. 
Subject Inclusion Criteria 
Patients are required to meet the following inclusion criteria before entering the study: 
1. Pathologically-confirmed diagnosis of locally advanced squamous cell carcinoma of the head 
and neck that will be treated with cisplatin plus concurrent IMRT. 
Note: Patients with unknown primary tumors whose treatment plan matches the requirements 
specified in Inclusion Criteria #2 and #3 below are eligible for the study. 
2. Treatment plan to receive a continuous course of IMRT delivered as single daily fractions of 
2.0 to 2.2 Gy with a cumulative radiation dose of 60-72 Gy. Planned radiation fields must 
include at least 2 oral sites (left and right buccal mucosa, floor of mouth, left and right lateral 
tongue, soft palate) that each receive a cumulative dose of at least 50 Gy.  
Note: Unavoidable doses of at least 50 Gy, to include entrance, exit, and scatter doses, still 
constitute planned radiation. 
3. Patients who have had prior surgery are eligible, provided they have fully recovered from 
surgery, and patients who may have surgery in the future are eligible. 
4. Treatment plan to receive standard cisplatin monotherapy administered either every three 
weeks (100 mg/m2 for 3 doses) or weekly (40 mg/m2 for 6-7 doses). The decision on which 
cisplatin regimen to use in combination with IMRT and GC4419 will be at the discretion of 
the Investigator. 
5. Age 18 years or older 
6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 
7. Adequate hematologic function as indicated by: 
• Absolute neutrophil counts (ANC) ≥ 1,500/mm3 
• Hemoglobin (Hgb) ≥ 9.0 g/dL 
• Platelet count ≥ 100,000/mm3 
8. Adequate renal and liver function as indicated by: 
• Serum creatinine acceptable for treatment with cisplatin per institutional guidelines 
• Total bilirubin ≤ 1.5  upper-normal limit (ULN) 
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5  ULN 
• Alkaline phosphatase ≤ 2.5  ULN 
9. Serum pregnancy test negative for women of childbearing potential 
10. Males and females must agree to use a highly effective contraception starting prior to the 
first day of treatment and continuing after the last dose of GC4419 for 30 days (females) or 
90 days (males) 
11. Properly obtained written informed consent 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 26 of 73 
7.2. 
Subject Exclusion Criteria 
Patients will be excluded if they meet any of the following exclusion criteria: 
1. Metastatic disease  
2. Prior radiotherapy to the region of the study cancer or adjacent anatomical sites or more than 
25% of total body marrow-bearing area (potentially interfering with chemo-tolerance) 
3. Prior induction chemotherapy or plans for chemotherapy to be administered only 
sequentially, not concurrently, with IMRT 
4. Planned concurrent chemotherapy other than single agent cisplatin 
5. Receiving any approved or investigational anti-cancer agent other than those provided for in 
this study 
6. Concurrent participation in another interventional clinical study or use of another 
investigational agent within 30 days of first dose of GC4419 
Note: Patients who are participating in non-interventional clinical studies (e.g., QOL, 
imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of 
participation. 
7. Inability to eat soft solid food at baseline for reasons other than mouth soreness after surgery 
or dental procedures 
8. Complete reliance on parenteral or gastrointestinal tube-delivered nutrition at baseline 
Note: Patients who have gastrostomy tubes prophylactically placed are eligible. Patients 
receiving supplemental nutrition through a gastrostomy tube at baseline may be eligible 
depending on diet. 
9. Malignant tumors other than head and neck cancer (HNC) within the last 5 years, unless 
treated definitively and with low risk of recurrence in the judgment of the treating 
Investigator 
10. Active infectious disease excluding oral candidiasis 
11. Presence of oral mucositis at baseline. Subjects with mouth or throat pain solely due to post-
operative effects are eligible, however. 
12. Known history of human immunodeficiency virus (HIV) or active hepatitis B/C (patients 
who have been vaccinated for hepatitis B and do not have a history of infection are eligible) 
13. Female patients who are pregnant or breastfeeding 
14. Known allergies or intolerance to cisplatin and similar platinum-containing compounds 
15. Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment 
of the treating Investigator, create a risk for a precipitous decrease in blood pressure. 
16. Medical history that includes any condition, or requires the use of concomitant medications 
which, in the Investigator’s judgment, are associated with or create a risk of increased 
carotid sinus sensitivity, symptomatic bradycardia, or syncopal episodes. 
7.3. 
Rationale for Patient Population 
Patients with locally advanced squamous cell cancer of the head and neck are appropriate 
candidates for concurrent chemoradiation as standard of care, with single-agent cisplatin perhaps 
the most widely accepted and widely used standard regimen. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 27 of 73 
Eligibility will include patients scheduled to receive the prescribed IMRT/cisplatin regimen 
either as definitive therapy or post-operatively. Both groups may be candidates for 
IMRT/cisplatin as standard care and the incidence of severe OM is expected to be similar for 
both groups. In addition, both have been included in the Phase 1 study, GT-001, the randomized 
Phase 2b study, GT-201 and the randomized Phase 3 study, GTI-4419-301. 
Patients with unknown primary tumor whose IMRT/cisplatin treatment plans conform to study 
requirements will be eligible. 
7.4. 
Screen Failures 
A subject is considered to be a screen failure if the subject signs the informed consent form but 
withdraws consent or is deemed ineligible before being enrolled to active treatment. The reason 
why the subject was precluded from the clinical study will be collected. All subjects who sign 
the informed consent form for this study, including screening failures, will be entered in the 
IXRS. 
7.5. 
Randomization Failures 
Not applicable.  
7.6. 
Subject Withdrawal Criteria 
In accordance with the Declaration of Helsinki, a subject has the right to withdraw from the 
study at any time for any reason. The Investigator may also, at his/her discretion, discontinue a 
subject from participating in this study at any time. Additionally, study treatment may be 
discontinued for any of the following reasons: 
• Adverse Event (AE) 
• Medical requirement to administer a contra-indicated medication 
• Subject non-compliance 
• Subject has a confirmed positive serum pregnancy test 
• Discontinuation of the study at the request of the Sponsor 
The primary reason for ceasing treatment with GC4419 will be clearly documented in the 
subject’s medical record and recorded on the appropriate CRF page. A subject who permanently 
discontinues treatment with GC4419 will not be allowed to be retreated. 
If a subject discontinues therapy as a result of an AE or serious adverse event (SAE), every 
attempt should be made to keep the subject in the study and continue to perform the required 
study-related follow-up and procedures. If this is not possible or acceptable to the subject, the 
subject may be withdrawn from the study. 
Subjects who withdraw consent for further administration of GC4419 should be encouraged to 
continue and complete their standard treatment with IMRT/cisplatin, and should be encouraged 
to continue with other study procedures. 
If a subject withdraws consent, additional details about the reasons for that decision will be 
sought and documented. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 28 of 73 
7.7. 
Study and Site Closure 
Both the Sponsor and the Investigator reserve the right to terminate the study at any time. Should 
this be necessary, both parties will arrange discontinuation procedures. In terminating the study, 
the Sponsor and the Investigator will assure that adequate consideration is given to the protection 
of the subjects’ interests. 
Upon completion of the study, the monitor will conduct the following activities in conjunction 
with the Investigator or site staff, as appropriate: 
• Return of all study data to the Sponsor (as applicable) 
• Resolution of all data queries 
• Accountability, reconciliation, and arrangements for all unused GC4419 
• Review of site study records for completeness 
• Shipment of laboratory samples (as applicable) 
In addition, the Sponsor reserves the right to temporarily suspend or prematurely discontinue this 
study either at a single site or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues or severe non-compliance. If the Sponsor determines such action is 
needed, the Sponsor will discuss this with the Investigator (including the reasons for taking such 
action) at that time. When feasible, the Sponsor will provide advance notification to the 
Investigator of the impending action prior to it taking effect. 
The Sponsor will promptly inform all other investigators and/or institutions conducting the study 
if the study is suspended or terminated for safety reasons and will also inform the regulatory 
authorities of the suspension or termination of the study and the reason(s) for the action. If 
required by applicable regulations, the Investigator must inform the IRB/IEC/Research Ethics 
Board (REB) promptly and provide the reason for the suspension or termination. If the study is 
prematurely discontinued, all study data must be returned to the Sponsor. 
Financial compensation to investigators and/or institutions will be in accordance with the 
agreement established between the Investigator and the Sponsor. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 29 of 73 
8. 
GC4419 
8.1. 
Description of GC4419 
8.1.1. 
GC4419 
GC4419 (Manganese,dichloro[(4aS,13aS,17aS,21aS)-
1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21a-eicosahydro-11,7-nitilo-7H-
dibenzo[b,h][1,2,7,10]tetraazacylcoheptadecine-κN5,κN13,κN18,κN21,κN22]-) is a water 
soluble, highly stable, low molecular weight manganese-containing macrocyclic ligand complex 
whose activity mimics that of naturally occurring SOD enzymes. 
GC4419 is formulated as a clear solution at the following concentration:  
• 90 mg GC4419: 9 mg/mL in 26 mM sodium bicarbonate-buffered 0.9 wt. % saline for 
parenteral administration. 
There are no other excipients.  
8.2. 
Treatment Assignment 
This is an open-label study.   
8.3. 
GC4419 Packaging and Labeling 
GC4419 will be presented in kits of 35 single-use vials, which represent 35 daily doses to be 
administered IV concurrent with IMRT.  
GC4419 is packaged as an 11 mL ± 0.1mL aliquot in a 10 mL amber glass vial with a S-127 
4432/50 gray stopper and a 20 mm red flip-off seal. Each bottle will be labeled with the 
appropriate language, including the required regulatory text.  Further label details will be 
provided in a separate Pharmacy Manual. 
8.4. 
GC4419 Storage 
GC4419 must be stored at 2°C to 8°C at all times until preparation. GC4419 must not be frozen 
at any time. Temperature excursions up to 25°C or down to 0.1°C for four hours are accepted; 
however, the Sponsor or its designee must be notified immediately of the temperature excursion 
to ensure proper oversight. 
Once prepared, the IV bags containing GC4419 saline mixtures must be administered to subjects 
within 24 hours of preparation. The GC4419 Infusion Solution should spend as little time as 
possible outside refrigerated conditions, not exceeding more than 6 hours at ambient 
temperature, and must not be frozen at any time. If freezing of the material is evident, that supply 
must be quarantined per institutional guidelines, and the Sponsor or its designee must be notified 
immediately. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 30 of 73 
8.5. 
GC4419 Preparation 
GC4419 will be provided to the study site in single use, sterile, pyrogen-free vials ready for dose 
preparation. Proper mixing with normal saline is required. Standard aseptic techniques will be 
used to maintain sterility. 
GC4419 will be presented in kits of 35 single-use vials, which represent 35 daily doses to be 
administered IV concurrent with IMRT. 
To prepare daily IV solutions, investigational pharmacists will extract 10 mL from a single vial 
and add to 250 mL normal saline. Note that there is no extraction of saline (i.e., the infusion 
solution volume will be 250 mL saline + 10mL volume of GC4419 for a total volume of 260 
mL). No additional modifications or adjustments are to be made to the infusion solution. 
Further information and preparation details will be provided in a separate Pharmacy Manual. 
8.6. 
GC4419 Administration 
GC4419 saline mixture will be administered intravenously at an infusion rate that totals 60 min 
(± 6 min to account for saline overfill) for the total dose assigned. Infusions of GC4419 must be 
administered using an infusion pump (i.e., not by drip rate). Infusion pump models are not 
specified and may be per institutional preference/standard. 
To facilitate administration of GC4419 according to the study schedule, an indwelling venous 
access device may be used, at the discretion of the treating Investigator. 
IMRT must be initiated as soon as possible upon completion of the GC4419 infusion, but no 
later than four hours following the end of the infusion. 
GC4419 will be given beginning on the first day of radiation and continuing daily, concurrent 
with each dose of IMRT, to a cumulative radiation dose of approximately 60-72 Gy. 
Table 2 outlines the chemoradiation and GC4419 administration schedules. Please note 
chemotherapy is not required to be administered on the study days listed in Table 2, as long as it 
follows a weekly or tri-weekly schedule. 
If IMRT is not administered on any given day due to a treatment break or unforeseen 
circumstances, GC4419 should not be administered on that day. Breaks in IMRT will be 
determined by the subject’s treating physician in accordance with standard of care. Subjects 
should resume GC4419 administration when IMRT resumes. On days when planned doses of 
both GC4419 and IMRT are not administered (e.g., due to a holiday site closure), GC4419 
dosing may be extended along with IMRT to make up the missed dose(s) to a maximum of 35 
doses of GC4419. If a fraction of IMRT is not administered for any reason after GC4419 has 
been administered, that day’s GC4419 will count as one of the 35 doses.

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 31 of 73 
Table 2: 
Chemoradiation and GC4419 Administration Schedule  
Example: 35 Doses of GC4419 (5 days/week over 7 Week Schedule) 
Treatment 
Week 1 
Week 2 
Week 3 
Week 4 
Day 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
8 
Day 
9 
Day 
10 
Day 
11 
Day 
12 
Day 
15 
Day 
16 
Day 
17 
Day 
18 
Day 
19 
Day 
22 
Day 
23 
Day 
24 
Day 
25 
Day 
26 
GC44191 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Cisplatin2 
Tri-Weekly 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
Weekly 
X 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
Radiation3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Treatment 
Week 5 
Week 6 
Week 7 
Day 
29 
Day 
30 
Day 
31 
Day 
32 
Day 
33 
Day 
36 
Day 
37 
Day 
38 
Day 
39 
Day 
40 
Day 
43 
Day 
44 
Day 
45 
Day 
46 
Day 
47 
GC44191 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Cisplatin2 
Tri-Weekly 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
Weekly 
X 
 
 
 
 
X 
 
 
 
 
X4 
 
 
 
 
Radiation3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
1 Intravenous GC4419 is administered by a 60-minute intravenous infusion (±6 min) once a day for the first 35 days of IMRT (Monday through Friday). IMRT 
must be initiated as soon as possible upon completion of GC4419 infusion, but no later than four hours post GC4419 infusion. On Day 1/Baseline, chemotherapy 
prehydration and infusion should be administered after GC4419 infusion and IMRT, if possible, to ensure that IMRT is initiated within four hours of the GC4419 
infusion stop. If IMRT is not received on any given day due to a treatment break or unforeseen circumstances, GC4419 should not be administered on that day. 
Subjects should resume GC4419 administration when IMRT resumes. If a subject is scheduled to receive IMRT on a weekend day (e.g., to make-up for a holiday 
site closure), the Investigator should contact the Medical Monitor for a discussion prior to IMRT administration. 
2 Cisplatin monotherapy should be administered in a standard q3 weeks regimen (100 mg/m2) or weekly regimen (40 mg/m2). Anti-emetic prophylaxis and 
hematopoietic growth factor use should be administered per ASCO guidelines. If institutional guidelines permit, cisplatin may be administered prior to or after 
the first day of IMRT. On days in which chemotherapy and GC4419 are administered, the administration sequence should be GC4419, IMRT, prehydration, and 
then cisplatin, if possible, to ensure that IMRT is initiated within four hours of the stop time of GC4419 infusion. Patients treated with induction chemotherapy 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 32 of 73 
prior to concomitant chemoradiation are not eligible for this study, nor are people for whom chemotherapy and radiation are only to be administered sequentially, 
not in a concurrent regimen. 
3 Eligible patients will be scheduled to receive a continuous course IMRT delivered in single daily fractions of 2.0 to 2.2 Gy, five days per week (Monday 
through Friday), with a cumulative radiation dose of 60-72 Gy. Planned radiation treatment fields must include at least two oral sites (buccal mucosa, floor of 
mouth, tongue, soft palate) that are each planned to receive > 50 cumulative Gy. 
4 The 7th dose of cisplatin will only be administered if the subject is on the 7-dose weekly cisplatin schedule (weekly cisplatin schedule may be 6 or 7 doses, 
depending on Investigator choice). 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 33 of 73 
8.7. 
GC4419 Accountability and Compliance 
Compliance with GC4419 dosing, including administration details (e.g., volume, start, stop 
times, etc.) should be documented in the source documents and recorded on the CRF. 
The Investigator is responsible for ensuring adequate accountability of all used and unused 
GC4419. This includes acknowledgment of receipt of each shipment of GC4419 (quantity and 
condition), subject dispensing records, and quantity of GC4419 returned or destroyed. 
Dispensing records will document quantities received from the Sponsor and quantities dispensed 
to subjects, including container number or lot number, date dispensed, subject identifier number, 
and the initials of the person dispensing the medication. Any GC4419 that is prepared but not 
used must also be recorded in the dispensing records. 
All GC4419 supplies and associated documentation will be reviewed and verified by the study 
monitor. Copies of all forms, documenting drug receipt at the study site, drug transportation to 
satellite sites, and drug return to the Sponsor, together with drug accountability records, will be 
retained according to the regulations governing record retention. 
The Investigator will not allow GC4419 to be given to any patient not included in the study or to 
any unauthorized person. 
8.8. 
GC4419 Handling and Disposal 
All used GC4419 containers are to be retained by the site until notified by the study monitor, 
who will instruct the site in the disposal and/or destruction of all used GC4419 supplies.  
After completion of the study, all unused GC4419 will be inventoried and, if possible, destroyed 
locally at the site. GC4419 should not be returned directly to the Sponsor unless specifically 
requested by the Sponsor. The study monitor will instruct the site in the disposal and/or 
destruction of all used and unused GC4419 supplies. Destruction of any GC4419 should be 
documented appropriately. 
8.9. 
Concomitant Medications 
All concomitant therapies (i.e., prescription and over-the-counter medications) taken by subjects 
from the date of enrollment through 30 days following the last GC4419, IMRT or cisplatin dose 
(i.e., whichever occurs last) will be collected in the CRF. Additionally, any concomitant 
therapies if used to treat any serious or related adverse event will be recorded in the CRF. 
Anti-emetic prophylaxis and hematopoietic growth factors should be used per ASCO guidelines 
(Hesketh, Kris et al. 2017). 
Subjects who withdraw consent for GC4419 should be encouraged to continue and complete 
standard IMRT/cisplatin treatment and other protocol procedures. 
However, if a subject withdraws consent for the study or is removed from the study completely 
(i.e., the subject is no longer participating in any study procedures or follow-up) no further data 
should be collected after the date of the subject’s study discontinuation.   

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 34 of 73 
8.9.1. 
Prohibited Medications 
Investigators may prescribe concomitant medication or supportive therapy deemed necessary to 
provide adequate supportive care for complications other than OM (e.g., antiemetics, systemic 
antibiotics, hydration to prevent renal damage, etc.). 
Hematopoietic growth factor use is permitted per ASCO guidelines.  Following the ASCO (and 
MASCC) guidelines for the prevention and management of chemotherapy-induced nausea and 
vomiting (CINV) is strongly encouraged.  See Table 6 (Appendix 5). 
Oral care per MASCC/ISOO Oral Care Education Materials (summarized in Appendix 6) is 
strongly recommended for all subjects as part of standard of care.  Oral topical lidocaine is 
permitted.   
Diphenhydramine (Benadryl®) administered as tablets or by injection is permitted. 
The following must not be used: 
• Nitrates, phosphodiesterase type 5 (PDE 5) inhibitors (e.g., sildenafil, tadalafil, or similar 
agents) or other drugs that in the judgment of the treating Investigator could create a risk 
of a precipitous decrease in blood pressure are prohibited until at least 24 hours after the 
last dose of GC4419 
• Pyridostigmine or other drugs that in the judgment of the treating Investigator could 
create a risk of increased carotid sinus sensitivity, symptomatic bradycardia, or syncopal 
episodes. 
• Palifermin (Kepivance®) or another keratinocyte or fibroblast growth factor 
• Amifostine (Ethyol®) 
• Benzydamine (Difflam®, Pharixia®, Tantum Verde) 
• Low-level laser treatment  
• Glutamine applied topically 
• GM-CSF applied topically 
• ‘Mouthwashes’ that include the following:  
− Chlorhexidine 
− Hydrogen peroxide 
− Diphenhydramine (Benadryl®) liquid formulation 
− Tetracycline 
− Any other listed disallowed medications 
• MuGard™, Gelclair®, Episil®, or other barrier devices 
• Caphosol® 
• Povidone-iodine rinses 
• Steroid rinses 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 35 of 73 
• Sucralfate in suspension form (use of sucralfate tablets is not proscribed) 
• Biologic response modifiers – except systemic hematopoietic growth factors for the 
management of anemia or myelosuppression 
• Concurrent approved or investigational anti-cancer therapy (e.g., chemotherapy, 
immunotherapy, targeted therapy, hormone and biologic therapy) other than the Protocol 
regimen 
• Other investigational agents 
In vitro, GC4419 inhibited cytochrome P450 isozyme 2D6 (CYP2D6) with an IC50 of 0.079 
µM. Concurrent administration of GC4419 with CYP2D6 substrates should be done with 
caution, and the need for a decreased dose of the CYP2D6 substrate should be 
considered, especially for substrates with a narrow therapeutic range. CYP2D6 substrates include 
certain beta blockers (e.g., propranolol and metoprolol), antidepressants (e.g., tricyclics), 
antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, 
flecainide). 
Mouthwashes or rinses containing sodium bicarbonate, clotrimazole (Mycelex), nystatin, 
fluconazole (Diflucan), viscous xylocaine, and/or viscous lidocaine are permitted. If a subject 
uses “Magic Mouthwashes” or “Miracle Mouthwashes,” all ingredients must be recorded in the 
subject’s medical record in order to confirm the mouthwashes did not contain the prohibited 
ingredients listed above. 
All medication restrictions end after post-IMRT OM follow-up is completed unless otherwise 
noted. 
Subjects who receive prohibited medications will not automatically be removed from the study; 
however, administration of a prohibited medication is a significant deviation from the protocol 
and must be reported to the Medical Monitor as soon as possible and the presiding IRB/IEC/REB 
(per institutional guidelines). The decision for study continuation or discontinuation will be made 
at that time on a case-by-case basis and in consideration of the clinical requirement and 
circumstances. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 36 of 73 
9. 
TOXICITY MANAGEMENT 
9.1. 
Dose Delays and Dose Modifications for Toxicity 
Toxicities requiring a 25% dose reduction: 
• Grade 2 or greater hypotension within 2 hours after the start of GC4419 infusion 
• Grade 3-4 adverse events (AEs) judged by the Investigator to be likely attributable to the 
study infusion. 
Dose reductions of GC4419 should be done in increments of 25% of the starting dose.  Two dose 
reductions for toxicity will be permitted per subject. After the first event, the subject will be re-
challenged at 75% of the original dose (7.5 mL GC4419 in 250 mL normal saline). After the 
second event, the subject will be re-challenged at 50% of the original dose (5.0 mL GC4419 in 
250 mL normal saline). Subjects who are unable to tolerate GC4419 infusions following 2 dose 
reductions must be discontinued from the study treatment but should continue with 
cisplatin/IMRT and other study assessments and procedures, with the concurrence of the treating 
Investigator, if the subject maintains informed consent to do so. 
For other toxicities (including those attributable to cisplatin and IMRT), management will be per 
institutional and ASCO guidelines and Investigator judgment. 
The Sponsor strongly recommends managing treatment modifications for cisplatin related 
toxicities by reducing the dose and/or altering the schedule of cisplatin administration. Such 
modifications may be made per the judgment of the treating Investigator. However, substitution 
of other systemic agents (e.g., carboplatin with or without paclitaxel, cetuximab, etc.) is not 
consistent with the protocol and should not be done.  
OM will not be considered an AE requiring dose modification for the purposes of this study. 
9.2. 
Supportive Care Guidelines 
Necessary supportive measures for optimal medical care will be given throughout the study. 
Supportive care medications may be administered at the Investigator's discretion and recorded in 
the CRF (including administration of prophylactic antiemetic medication if deemed appropriate 
by the Investigator). However, medications are subject to the exclusions listed in Section 8.9.1. 
9.2.1. 
Supportive care for chemotherapy-induced nausea and vomiting (CINV) 
Medication to prevent or manage chemotherapy-induced nausea and vomiting (CINV) should 
follow recent guidelines from ASCO and MASCC (Appendix 5). Adult patients who are treated 
with cisplatin (considered a high-emetic-risk single agent for the purposes of these guidelines) 
should be offered a four-drug combination of a NK1 receptor antagonist, a serotonin (5-HT3) 
receptor antagonist, dexamethasone, and olanzapine. Dexamethasone and olanzapine should be 
continued on days 2 to 4. (Type: evidence based, benefits outweigh harms; quality of evidence: 
high; strength of recommendation: strong.) (Hesketh, Kris et al. 2017). 
Supportive care for CINV should be optimized, per ASCO and MASCC guidelines, before 
GC4419 dose is reduced for nausea and vomiting. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 37 of 73 
10. 
ASSESSMENTS 
The study procedures to be conducted for each subject enrolled in the study are described in the 
text that follows and summarized in the Schedule of Assessments in Appendix 1. 
Adherence to the study design requirements, including those specified in the Schedule of 
Assessments, is required for study conduct.  
Any deviation from protocol procedures should be explained in the source documents. The 
Sponsor (or designee) and the site’s institutional review board (IRB/IEC/REB) – as required by 
the IRB/IEC/REB policies and procedures – should be notified as soon as possible of any 
deviations potentially affecting subject safety, GC4419 administration or the assessment of 
safety, efficacy and tolerability parameters. 
All screening evaluations must be completed and reviewed to confirm that the potential 
participants meet eligibility criteria before enrollment.  The investigator will maintain a 
screening log to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, if applicable.   
10.1. 
Safety Assessments 
Safety will be assessed on the basis of treatment-emergent AEs, physical examination findings, 
clinical laboratory tests, electrocardiogram (ECG) measurements, and vital sign measurements. 
10.1.1. 
Clinical Assessments 
The following clinical assessments are defined when referenced in the schedule of events for this 
study: 
• 12-Lead ECG: ventricular rate, P-R interval, QRS interval, QT interval, and QTc 
• Vital signs: measured following two minutes of rest in the sitting position – temperature, 
systolic and diastolic blood pressures, heart rate and respiration rate.  Vital signs are 
required to be taken at Screening, Day 1 (Baseline), once during Week 4, once during 
Week 7 and any additional IMRT weeks, and on the Last Day of IMRT.  
• Blood Pressure:  On Day 1 (Baseline) and Day 22, blood pressure must be measured at 
the following times: 
− Within 30 minutes prior to the pre-GC4419 PK draw, and 
− After GC4419 infusion, prior to standing and prior to the End of GC4419 Infusion PK 
draw. 
• Weight and Height: measured in kilograms (kg) and centimeters (cm), respectively 
• Performance Status: ECOG assessment to be performed at Screening, Day 1 (Baseline), 
once during Week 4, once during Week 7 and any additional IMRT weeks, and on the 
Last Day of IMRT (see Appendix 3 for conversion criteria for Karnofsky to ECOG). 
10.1.2. 
Laboratory Assessments 
All protocol required clinical laboratory assessments should be performed at the central 
laboratory.  

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 38 of 73 
The Investigator must assess all abnormal clinical laboratory results for clinical significance in a 
timely fashion. A notation of clinically significant (CS) or non-clinically significant (NCS) with 
initials and date will be documented on the respective laboratory report next to any abnormal 
value. Information on laboratory AE reporting can be found in Section 11.2. 
The following laboratory assessments are defined when referenced in the schedule of events 
(Table 5) for this study: 
• Hematology Profile: hemoglobin, hematocrit, red blood cell count, white blood cell count 
with differential, and platelet count. Differential to include total neutrophils, 
lymphocytes, monocytes, eosinophils, and basophils. 
• Serum Chemistry Profile: glucose, blood urea nitrogen (BUN), creatinine, sodium, 
potassium, calcium, albumin, total protein, direct bilirubin, total bilirubin, alkaline 
phosphatase, ALT (SGPT), AST (SGOT), chloride, phosphate, bicarbonate, magnesium. 
• Serum Pregnancy Test: required for all women of childbearing potential. Lack of 
childbearing potential must be noted in the source documents, if applicable. 
• Urine Pregnancy Test:  required for women of childbearing potential. Lack of 
childbearing potential must be noted in the source documents, if applicable. 
10.2. 
Symptom Related Questionnaires 
Subjects will be asked to complete a brief questionnaire (Appendix 7) at Baseline and then once 
weekly before the second oral assessment of each week during treatment and 4 weeks after the 
end of treatment.  On the days of the questionnaire completion, the study staff member should 
provide the questionnaire worksheet to the subject for completion prior to the OM assessment 
and should review the worksheet for completion.   
The subjects’ reported symptoms will support hypothesis generation surrounding the potential 
effects of GC4419 on long term OM related symptoms.   
10.3. 
Oral Mucositis Assessments 
OM assessments will be completed at the Screening Visit (within 28 days of IMRT start), 
Baseline Visit, twice weekly (no less than two days apart) within each five-day IMRT treatment 
period and once weekly for four weeks following end of treatment.  
The extent of subjects’ OM will be assessed by a trained evaluator and scored using the WHO 
OM toxicity scoring scale (Appendix 2). All subjects must have an oral assessment on the last 
day of IMRT treatment. If a subject withdraws for any reason prior to the end of IMRT, a 
complete oral assessment should be done on that day. 
Study site personnel will be provided with specific training and instructions regarding OM 
assessment performance, grading, and documentation. Designated trained study staff (oral 
evaluators) will conduct all assessments using a standardized and consistent method. To reduce 
inter-observer variability, the fewest possible number of evaluators should be involved in the 
assessments of each subject. The oral evaluators will use a Sponsor-provided headlamp for all 
oral assessments conducted for this study.  

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 39 of 73 
The WHO scale will be the measure for assessing OM. The assessment of the impact of OM on a 
subject’s ability to eat is critical for accurate scoring of the WHO scale. Therefore, 
standardization of the assessment is very important.  A third-party vendor will perform data 
quality management for all OM scoring.  This process will be outlined in a separate study 
document. 
In order to reduce variability in assessing food intake, the definitions for solids, liquids, and 
nothing by mouth are provided here: 
• Solid foods are defined as foods that need to be chewed. Examples include meat, grains 
and vegetables. 
• Liquids are defined as foods that take the shape of their container. Examples include fruit 
juices, soups, pureed foods, mashed potatoes, cooked cereals (oatmeal), baby food, Jell-
O®, pudding, and ice cream. 
• Nothing by mouth is defined as no eating or drinking, except enough liquid to allow for 
taking medications. 
The WHO scoring scale is appended in Appendix 2. 
10.4. 
Radiation Therapy Quality Assurance 
An independent radiation oncologist who is not an Investigator on the study will review the 
overall treatment plan, for summary and retrospective analysis at the end of the study. In addition 
to IMRT treatment, dosimetry and dose volume histograms will be collected after simulation. 
The 50-Gy isodose line should be clearly indicated, along with relevant imaging through the 
anatomic region for planned treatment.   
10.5. 
Pharmacokinetic (PK) Measurements of GC4419 
PK sampling for GC4419 will be sought from all subjects for GC4419.  Plasma samples for 
GC4419 PK measurements will be collected during Cycle 1 and Cycle 4 on Study Days 1 and 2 
(Cycle 1), and on Study Day 22 (Cycle 4).  
On Study Days 1 and 22, four samples will be drawn as follows: 
• The first sample will be drawn prior to GC4419 administration. 
• The second sample will be drawn within 10 minutes after the end of GC4419 infusion. 
• The third sample will be drawn within 10 minutes after the end of IMRT. 
• The fourth and final sample will be drawn between 60 and 180 minutes after the end of 
• GC4419 infusion. 
On Study Day 2 only one PK sample will be drawn.  
• This sample should be drawn prior to the GC4419 infusion on Day 2. 
Table 3 below summarizes the PK sample collection time points. Note that this schedule may be 
adjusted to accommodate mid/late-week study starts and holidays. Adjustments in the PK 
schedule must be discussed with the Sponsor or its representative ahead of time. Time of actual 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 40 of 73 
blood draws for PK assessment must be recorded in the source notes. Plasma PK samples will be 
sent to a central laboratory for analysis and interpretation. Further details on PK sample 
collection, processing, and shipping are provided in a separate manual. Volumes and start/stop 
times for administration of IV fluids will be collected on PK sampling days. 
Table 3: 
Pharmacokinetic Sampling Schedule to Assess GC4419 
Timepoint 
Day 1 
Day 2 
Day 22 
Pre-GC4419 
X 
X 
X 
End of GC4419 (+10 min) 
X 
 
X 
60-180 min Post End of GC4419 Infusion 
X 
 
X 
Post-IMRT (+10min) 
X 
 
X 
10.6. 
Tumor Status Assessment 
10.6.1. 
Tumor Imaging 
10.6.1.1. Pre-Treatment Tumor Imaging 
Radiographic tumor imaging should occur within 60 days prior to the first day of IMRT 
(Baseline), and should be conducted according to local standard of care to ensure consistency 
with eligibility criteria. One of the following imaging combinations is recommended: 
• CT scan of the neck with contrast plus chest CT with or without contrast 
• MRI scan of the neck with contrast plus chest CT with or without contrast 
• CT scan of the neck with contrast plus PET/CT of the neck and chest with or without 
contrast 
• MRI scan of the neck with contrast plus PET/CT of the neck and chest with or without 
contrast 
If the subject has no evidence of disease at Baseline, it should be clearly indicated. 
10.7. 
Schedule of Time and Events 
A schedule of study assessments table is located in Appendix 1, Table 5. Minor changes to the 
assessment schedule may be made to accommodate holidays, administrative closures, etc., which 
if necessary, are not considered deviations by the Sponsor. Sites should contact the Sponsor (or 
its representative) prospectively to address rescheduling protocol assessments and data handling. 
10.7.1. 
Screening 
Screening assessments and procedures will be completed within 28 days of IMRT and GC4419 
start.   
• Obtain a signed IRB/IEC/REB-approved informed consent form (ICF) 
• Confirm subject eligibility by reviewing inclusion/exclusion criteria 
• Ensure a dental examination was conducted for IMRT clearance and potential sources of 
mucosal irritation (e.g., tooth extraction) were eliminated. The dental exam must occur 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 41 of 73 
within the 28-day screening period. The exam must be performed by a licensed clinician, 
but not necessarily by a dentist. For edentulous subjects, the subject must be cleared for 
IMRT per SOC (i.e., oral exam). 
• Obtain medical history, tobacco use history, and alcohol use history 
• Obtain HNC history; HNC history should include: 
− Tumor HPV status, for oropharyngeal cancers 
− Pre-treatment tumor imaging (See Section 10.6.2.1); may be completed within 
60 days prior to the first day of IMRT)   
− Prior treatments 
− Confirmation of histopathological diagnosis of SCC 
− Tumor staging (AJCC 8th Edition) (pre-surgical staging for surgical subjects if 
available; otherwise, provide post-surgical staging) 
• Conduct a complete physical examination, including height 
• Measure vital signs, body weight, and ECOG Performance Status 
• Confirm required Radiographic imaging performed within 60 days prior to first day of 
IMRT per Section 10.6.1.1. 
• Conduct a 12-lead ECG.   
• Conduct OM assessment per Appendix 2 and record the WHO score 
• Draw blood for clinical laboratory measurements per Section 10.1.2 to include 
hematology profile, serum chemistry profile and serum pregnancy test for women of 
childbearing potential 
• Record planned IMRT and chemotherapy parameters 
• Record/update medical conditions and illnesses that have occurred since the subject 
signed the ICF and record in medical history 
• All questions related to subject eligibility should be directed to Galera’s Medical Monitor 
or designee. 
10.7.2. 
Treatment Phase 
10.7.2.1. Prior to GC4419 Infusion  
Prior to receiving the first dose of GC4419 the following observations and procedures will be 
conducted for all subjects: 
• Confirm continued subject eligibility by reviewing inclusion/exclusion criteria (IMRT 
Week 1 Day 1 only) 
• Record/update medical conditions and illnesses that have occurred since the subject 
signed the ICF and record in medical history including a review of tobacco and alcohol 
use (Week 1 Day 1 only) 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 42 of 73 
• Complete Physical Exam (Last Day of IMRT regimen or Early Termination Visit Only) 
• Body Weight (Week 1 Day 1, once weekly during Treatment Phase, and Last Day of 
IMRT or Early Termination Visit) 
• Vital signs to be obtained at Week 1 Day 1, once during Week 4 and once during Week 7 
and any additional IMRT weeks, and Last Day of IMRT or Early Termination Visit to 
include temperature, systolic and diastolic blood pressures, heart rate and respiration rate 
On Day 1 (Week 1) and Day 22 (Week 4), blood pressure must be measured at the following 
times: 1) within 30 minutes prior to the pre-GC4419 PK draw, and 2) after GC4419 infusion, 
prior to standing and prior to the End of GC4419 Infusion PK draw. 
• ECOG Performance Status to be evaluated at Baseline Visit, once during Week 4 and 
once during Week 7 
• Record BSA at Week 1 Day 1, and once during Weeks 4 and 7 for tri-weekly cisplatin 
dosing or once per week for subjects receiving weekly cisplatin.   
• Conduct clinical tumor assessment per Section 10.6.1 Last Day of IMRT regimen or 
Early Termination Visit Only) 
• Ensure concomitant medications have been recorded from date of enrollment 
• Ensure AEs have been recorded from date of enrollment 
• OM assessment using the WHO OM toxicity scale (Appendix 2) beginning on Week 1 
Day 1 and then twice weekly thereafter (no less than two days apart) within each 5-day 
IMRT period, and Last Day of IMRT or Early Termination Visit.   
• Draw blood for clinical laboratory measurements per Section 10.1.2 to include 
hematology profile and serum chemistry profile (Week 1 Day 1, Day 3, 4 or 5 and once 
per week thereafter through the last day of IMRT.  Note:  If safety labs have not been 
drawn during the study week in which the last day of IMRT regimen/Early Termination 
Visit occur, then the clinical laboratory measurements should be collected at that time.   
• Urine Pregnancy Test on Week 1 Day 1 and Week 4 Day 1 
• Draw blood for Pre-dose PK sampling per Section 10.1.1, Table 3 (Day 1, Day 2 and Day 
22 only) 
• Serum Pregnancy Test for women of childbearing potential on Last Day of IMRT or 
Early Termination Visit. 
10.7.2.2. GC4419 Infusion  
• Administer GC4419 dose by continuous intravenous infusion over 60 minutes weekly, 
Monday through Friday, beginning at Week 1 Day 1 and continuing through 35 doses.  
See Section 8.6, Table 2. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 43 of 73 
10.7.2.3. Following GC4419 Infusion  
Following GC4419 administration the following observations and procedures will be conducted 
for all subjects: 
• Measure Blood Pressure prior to standing (Week 1 Day 1 and Day 22 only) 
• Draw blood for End of GC4419 Infusion (+10 minutes) PK sampling (Week 1 Day 1 and 
Day 22 only) 
• Administer IMRT as soon as possible but no later than four hours following the end of 
GC4419 dosing.  On days on which chemotherapy and GC4419 are administered, the 
following administration sequence should be used when possible to ensure that IMRT is 
initiated within four hours of the stop time of GC4419 infusion: GC4419, IMRT, 
prehydration, and cisplatin. 
• Draw blood for Post IMRT (+10 minutes) PK sampling (Week 1 Day 1 and Day 22 only) 
• Draw blood for 60-80 Minutes Post End of GC4419 Infusion PK sampling  
10.7.3. 
Follow-up Phase 
10.7.3.1. Post-IMRT OM Follow Up  
All subjects will be evaluated weekly (± 2 calendar days) for the four weeks post-IMRT.  At 
each visit, the following should be completed:  
• Conduct OM assessment and record the severity using the WHO score 
• Record AEs and concomitant medications through 30 days following the last dose of 
IMRT, cisplatin, or GC4419 (i.e., whichever occurs last) 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 44 of 73 
11. 
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
The Investigator is responsible for the detection and documentation of events meeting the criteria 
and definition of an AE or SAE as provided in this protocol. Throughout the study, AEs will be 
recorded in the source documents and on the appropriate pages of the CRF regardless of whether 
the AEs are considered related to GC4419. To avoid confusion, the AE should be recorded in 
standard medical terminology. 
11.1. 
Definitions 
The following definitions of terms are guided by the ICH and the US CFR and are included here 
verbatim. 
11.1.1. 
Adverse Event (AE) 
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have a causal relationship 
with this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product. 
Examples of an AE include: 
• Significant or unexpected worsening or exacerbation of the condition/indication under 
study. 
• Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity (grade) of the condition. 
• New conditions detected or diagnosed after investigational product administration even 
though they may have been present prior to the start of the study. 
• Signs, symptoms, or the clinical sequelae associated with a suspected interaction of the 
investigational product with a concomitant medication. 
• Signs, symptoms, or the clinical sequelae associated with a suspected overdose of either 
investigational product or a concurrent medication. 
11.1.2. 
Serious Adverse Event (SAE) 
Any untoward medical occurrence that at any dose: 
• Results in death, 
• Is life-threatening 
Note: The term ‘life-threatening’ in the definition of ‘serious’ refers to any adverse drug 
experience [adverse event] that places the patient or subject, in the view of the 
Investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not 
include a reaction that, had it occurred in a more severe form, might have caused death. 
[emphasis added] 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 45 of 73 
• Requires inpatient hospitalization or prolongation of hospitalization  
Note: In general, hospitalization signifies that the patient or subject has been detained 
(usually involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE 
should be considered serious. Hospitalization for elective treatment of a pre-existing 
condition that did not worsen from baseline is not considered an AE. 
• Results in persistent or significant disability/incapacity  
Note: The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. 
OR 
• Is a congenital abnormality/birth defect. 
11.2. 
Adverse Event Reporting Requirements 
11.2.1. 
Serious Adverse Events 
All events meeting the criteria for Serious Adverse Events (see Section 11.1.2) must be reported 
by investigational sites within 24-hours of becoming aware of the event. In order to determine 
the timeline for notifying the appropriate regulatory authorities and investigators, an event term, 
serious criteria, and causality is required at the time of the initial report. Specific SAE reporting 
instructions are provided in the SAE Report Completion Guidelines. 
The Investigator is responsible for notifying the IRB/IEC/REB in writing of serious events as 
soon as is practical in accordance with the policy of the IRB/IEC/REB. 
11.2.2. 
Collection Period for AEs and SAEs 
Any adverse medical condition or laboratory abnormality with an onset date prior to the date and 
time the subject received his/her first dose of study drug, GC4419, is considered pre-existing in 
nature and should be recorded as part of the subject’s medical history. An adverse medical 
condition that begins on or after the first dose of study drug will be considered an adverse event, 
and will be considered an SAE if it meets serious criteria. AEs and SAEs will be followed for 30 
days after the last dose of IMRT, cisplatin, or GC4419 (i.e., whichever occurs last), hereafter 
referred to as the “30-Day Follow-up Period”. Similarly, new events will be reported as 
AEs/SAEs if the start date is within the 30-Day Follow-up Period. Increases in toxicity grade of 
pre-existing conditions that occur on or after the first study drug administration are also 
considered adverse events. 
All adverse events must be recorded in the subject’s source documents and on the CRF 
regardless of frequency, severity (grade) or assessed relationship to therapy. Additionally, SAEs 
must be submitted to the Safety vendor within 24 hours of awareness. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 46 of 73 
11.2.3. 
Clinical Laboratory Abnormalities and Other Abnormal Assessments as AEs 
and SAEs 
Clinically significant abnormal laboratory findings or other abnormal assessments that are 
associated with the disease being studied, unless judged by the Investigator as more severe than 
expected for the subject’s condition, or that are present or detected at the time of enrollment and 
prior to study drug dosing that do not worsen, will not be reported as AEs or SAEs. 
Laboratory abnormalities should only be recorded in the Adverse Event section of the CRF if at 
least one of the following criteria is met: 
• Meets the criteria of an SAE 
• Resulted in a dose reduction and/or delay in the administration of GC4419, IMRT, and/or 
cisplatin 
• Treatment is initiated for the abnormality 
• Investigational product was discontinued 
• Grade 3 or Grade 4 per NCI CTCAE v5.0 
All other abnormal laboratory findings will be captured via laboratory CRF pages and noted in 
shift tables. 
Abnormal assessments (e.g., ECGs) that are judged by the Investigator as clinically significant 
will be recorded as AEs or SAEs if they meet the definitions as defined in Section 11.1. 
11.2.4. 
Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs 
or SAEs 
Oral mucositis will not be reported as an AE as it is captured as a study endpoint in the CRF. 
Progressive disease found by scan or on clinical evaluation should be captured on the applicable 
CRF pages and not recorded as an AE. 
11.2.5. 
Grading of Adverse Events 
The severity of adverse events will be designated as mild, moderate, severe, life threatening, or 
fatal per NCI CTCAE version 5.0. If not specifically addressed in NCI CTCAE version 5.0, use 
Table 4 below: 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 47 of 73 
Table 4: 
Adverse Event Severity 
Grade  
Criteria1 
Mild – Grade 1 
Asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated 
Moderate – Grade 2 
Minimal, local, or noninvasive intervention indicated; limiting 
age-appropriate instrumental ADL2 
Severe – Grade 3 
Severe or medically significant but not immediately life-
threatening; hospitalization or prolongation of hospitalization 
indicated; disabling; limiting self-care ADL3 
Life Threatening – Grade 4 
Life-threatening consequences; urgent intervention indicated 
Death – Grade 5 
Death related to adverse event 
1  A semi-colon indicates ‘or’ within the description of the grade. 
2  Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc. 
3  Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden. 
11.3. 
Relationship to Study Drug 
All AEs will be categorized by the Investigator with respect to their relationship to GC4419. The 
Investigator should consult the current IB and/or product information in the determination of 
his/her assessment. The relationship between GC4419 and the AE may be considered related, 
possibly related, or unrelated. The criteria for each category are listed below: 
• Related: It is likely that GC4419 caused or contributed to the cause of the adverse event 
or laboratory abnormality, when the temporal sequence from the time of GC4419 
administration, the known consequences of the subject’s clinical/state condition or study 
procedures, the effects of discontinuing or reintroducing GC4419 on the adverse event, 
and other medically relevant factors are considered. 
• Possibly Related: There is a reasonable possibility that the adverse event or laboratory 
abnormality was caused by GC4419, when the temporal sequence from the time of 
GC4419 administration, the known consequences of the subject’s clinical state/condition 
or study procedures, and other medically relevant factors are considered. 
• Unrelated: The Investigator has a high level of certainty that the subject’s clinical 
state/condition, study procedures, or other medically relevant factors other than treatment 
with GC4419 caused the adverse event or laboratory abnormality. This relationship 
category should only be used when a clear precipitating cause exists and it is not 
reasonably possible that the event is caused by treatment with GC4419. 
If the relationship between the AE/SAE and the investigational product is determined to be 
“possibly related” the event will be considered to be related to the investigational product for the 
purposes of expedited regulatory reporting. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 48 of 73 
11.4. 
Recording Adverse Events 
All AEs must be recorded on the appropriate CRF regardless of the severity or relationship to 
GC4419. All AEs that meet the seriousness criteria should also be recorded on the SAE Report 
Form. All SAEs must be reported to the Sponsor or delegated organization within the timeline 
stated in Section 11.2. 
The recording of AEs will be based on data obtained from the following sources: 
• Medical and surgical history 
• Physical examinations including vital signs 
• Clinical laboratory test results 
• Subject verbal reports to the investigational staff and documented in the medical chart 
All clinical events, including both observed (such as any reaction at sites of application) and 
volunteered problems, complaints, or symptoms, are to be recorded. The need to capture this 
information is not dependent upon whether the clinical event is associated with GC4419 use. 
AEs resulting from concurrent illnesses, reactions to concurrent medications or symptomatic 
progression of disease states, other than the disease under study, are also to be recorded. 
The information to be recorded for AEs will include: 
• The specific type of event in standard medical terminology – diagnosis if known, is 
preferred over symptoms 
• Duration of the clinical event (start and stop dates) 
• Severity (Grade 1, 2, 3, 4, or 5) of the clinical event 
• Seriousness (SAE) criteria, if applicable 
• Relationship of the AE to GC4419 as defined in Section 11.3 
• Management of GC4419 administration and other action taken to alleviate the clinical 
events 
• Clinical outcome of the AE 
11.5. 
Follow-up of AEs and SAEs 
If an adverse event changes in severity grade between the date it was initially recorded through 
the 30-Day Follow-up Period, the event should be recorded as a new AE; however, only one 
SAE should be reported to the Safety vendor for the event with the highest severity grade 
recorded. 
After the initial AE/SAE report, the Investigator is required to proactively follow each subject 
and provide further information on the subject’s condition. The Investigator will ensure that 
follow-up includes any supplemental investigations as may be indicated to elucidate the nature 
and/or causality of the AE or SAE. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 49 of 73 
Non-serious AEs that have not resolved within 30 days after last dose of GC4419 will be 
considered ongoing, and marked as such in the CRF. All SAEs will be followed until they 
resolve or a new baseline is established, at which point the appropriate CRF page(s) or SAE 
Report Form(s) will be updated. 
Routine collection of AEs will stop 30 days after last dose of GC4419, IMRT, or cisplatin (i.e., 
whichever occurs last); however, collection of clinical data will continue on events of interest or 
as clinical circumstances warrant that exceed the 30 days after last dose of GC4419, per below 
and described in other sections of the Protocol: 
• OM: 4 weeks post last IMRT dose (Section 10.7.3.1) 
• Medical events which in the opinion of the Investigator, serious and are believed to be a 
result of study participation to warrant notifying the Sponsor (Section 11.6 and 
Section 11.8). In these circumstances, the Investigator should contact the Galera Medical 
Monitor (or designee) directly to discuss the case, and how it should be reported. 
As reasonably requested by the Sponsor, the Investigator will perform or arrange for the conduct 
of supplemental measurements and/or evaluations to elucidate as fully as possible the nature 
and/or causality of the AE or SAE. If a subject dies during participation in the study or during a 
30-Day Follow-Up Period, the Sponsor will be provided with a copy of any post-mortem 
findings, including histopathology. 
11.6. 
Post-Study Reporting Requirements 
Although such information may not be routinely sought or collected by the Sponsor, SAEs that 
occur after the subject has completed a clinical study may be reported. Such cases will be 
evaluated for expedited reporting. 
11.7. 
Regulatory Reporting of Adverse Events 
The Sponsor, or its designee, is responsible for submitting reports of suspected, unexpected, 
serious adverse reactions (SUSARs) to regulatory authorities on an expedited basis, according to 
the International Council on Harmonisation Guidelines and to other regulatory authorities 
according to national and local regulations as required. 
The Investigator will report all SAEs that occur at his/her site to the IRB/IEC/REB per the 
IRB/IEC/REB regulations.  
Investigators will also be notified of SUSARs that occur at other Sponsor sites and Sponsor trials 
using the study product.  Each site is responsible for notifying its IRB/IEC/REB of these 
additional SUSARs in accordance with local or central IRB/IEC/REB procedures. Copies of 
each report will be kept in the Investigator’s files and adequate documentation will be provided 
to the Sponsor including documentation that the IRB/IEC/REB was notified of each safety 
report. 
11.8. 
Pregnancy 
The risks of treatment with GC4419 during pregnancy have not been evaluated. Male subjects 
and female subjects of childbearing potential who engage in sexual intercourse should use a 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 50 of 73 
highly effective method of contraception throughout the study and for 30 days (females) or 90 
days (males) following the last dose of GC4419. 
For the purpose of this document, a woman is considered of childbearing potential (WOCBP), 
i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile.  
Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral 
oophorectomy.  A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.  
For the purpose of this document, a man is considered fertile after puberty unless permanently 
sterile by bilateral orchidectomy. 
A highly effective method of contraceptive is defined as any methods that can achieve a failure 
rate of less than 1% per year when used consistently and correctly are considered as highly 
effective birth control methods.  
Such methods include: 
• combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation: 
− oral 
− intravaginal 
− transdermal 
• progestogen-only hormonal contraception associated with inhibition of ovulation: 
− oral 
− injectable 
− implantable  
• intrauterine device (IUD) 
• intrauterine hormone-releasing system (IUS) 
• bilateral tubal occlusion 
• vasectomized partner 
• sexual abstinence  
11.8.1. 
Time Period for Collecting Pregnancy Information 
As permitted by IRB/EC/REB policies, any pregnancy that occurs from the first dose of GC4419 
up to 30 days after last dose (30-Day Follow-Up Period) should be reported using the appropriate 
form within 24 hours of learning of the subject’s pregnancy. The subject will be followed 
throughout the course of the pregnancy. Generally, follow-up will be no longer than 6 to 8 weeks 
following the estimated delivery date. Any premature termination of the pregnancy should be 
reported. If a pregnancy is identified outside the 30-Day Follow-Up Period, the Investigator may 
report using clinical judgment. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 51 of 73 
11.8.2. 
Action to be Taken if Pregnancy Occurs in a Female Partner of a Male Subject 
The Investigator will attempt to collect pregnancy information on any female partner of a male 
study subject who becomes pregnant while the male partner is participating in this study. In the 
case of paternal exposure, the investigator should obtain permission from the subject's partner in 
order to collect any pregnancy information. The Investigator will record pregnancy information 
on the appropriate form and submit it to the Sponsor within 24 hours of learning of the partner’s 
pregnancy. The partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to the Sponsor. Generally, 
follow-up will be no longer than 6 to 8 weeks following the estimated delivery date. Any 
premature termination of the pregnancy will be reported. If a pregnancy is identified outside the 
30-Day Follow-Up Period, the Investigator may report using clinical judgment. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 52 of 73 
12. 
STATISTICS 
12.1. 
General Considerations 
A separate Statistical Analysis Plan will provide technical details of the statistical analyses to be 
performed, in addition to the specifications in this protocol. In the event of discrepancies 
between the protocol and the Statistical Analysis Plan, the latter will control the analyses 
performed. 
All statistical analyses will be conducted with the SAS® software package version 9.2 or higher. 
12.1.1. 
Randomization and Stratification 
Not applicable.  
12.2. 
Sample Size 
The sample size is selected with the intent that it will contribute to an overall safety database of 
300 subjects with head and neck cancer who will, across all studies of GC4419, have received a 
full course of GC4419 at the intended dose (90 mg), schedule (1-hour infusion, 5 days/week, 
prior to IMRT), and duration (single course of 6-7 weeks) in combination with concurrent IMRT 
and cisplatin.  Up to 70 such subjects are expected to be needed to reach the total safety database 
of 300.  Enrolling up to 70 patients to the present study is expected to provide these subjects, 
assuming that approximately 10-20% will discontinue GC4419 before receiving it for at least 6 
weeks.  
The overall safety database size of 300 will allow for detection with 95% probability of adverse 
events of 1% true incidence in at least 1 subject. 
Enrollment may be adjusted to ensure an overall safety database size of 300 across the 
development program.  
12.3. 
Analysis Populations 
Safety and efficacy analyses will be conducted on an “intent to treat” (ITT) population, 
consisting of all enrolled subjects who receive at least one dose of GC4419, and on a "per 
protocol" population consisting of subjects who receive at least 60 Gy of IMRT and at least 5 
weeks (25 doses) of GC4419. 
Subjects who withdraw prior to any dosing will have their reasons for withdrawal noted. 
12.4. 
Safety Analysis 
AEs will be grouped by system organ class, high level term, and preferred term according to the 
Medical Dictionary for Regulatory Activities (MedDRA) dictionary. Incidence by subject will be 
tabulated for all treatment-emergent, serious, severe, and treatment-related adverse events. 
Detailed listings will be provided for all serious adverse events, deaths, and withdrawals due to 
adverse events. 
Laboratory measurements and vital signs will be summarized by treatment group at each of the 
protocol-specified time points. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 53 of 73 
Safety parameters will be summarized with descriptive statistics on the safety population, 
defined as the ITT population; viz., all subjects who received at least one dose of GC4419.  
Further details will be provided in the study’s Statistical Analysis Plan. 
12.5. 
Efficacy Analysis 
Overall rates of SOM/Grade 4 OM incidence and number of SOM/Grade 4 days will be 
summarized descriptively. 
12.5.1. 
Multiplicity 
Not applicable.  
12.5.2. 
Handling of Missing Data 
Subjects who withdraw consent for GC4419 administration should be encouraged to continue 
and complete standard IMRT/cisplatin, and protocol assessments.   
The study’s Statistical Analysis Plan will discuss the handling of missing data for subjects who 
lack WHO OM scores, who discontinue from the study without complete OM follow-up of 
WHO OM scores, and whose resolution date of severe OM is unknown. 
12.5.3. 
Covariate Adjustment 
Not applicable. 
12.6. 
Exploratory Analyses 
Any exploratory analyses will be described in the Statistical Analysis Plan. 
12.7. 
ETHICS 
12.7.1. 
Ethical Conduct of the Study 
The Investigator will ensure that this study is conducted in full compliance with the principles of 
the “Declaration of Helsinki” (version October 2008), ICH guidelines, in particular ICH-GCP, or 
with the laws and regulations of the country in which the research is conducted, whichever 
affords the greatest protection to the study subject. The Investigator will also assure that the basic 
principles outlined in “ICH Guideline for Good Clinical Practice” as published in the Federal 
Register May 9, 1997, and all applicable Federal regulations are adhered to. 
12.7.2. 
Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC)/Research Ethics Board (REB) Approval 
This protocol and any accompanying material to be provided to the subject (such as 
advertisements, information sheets, or descriptions of the study used to obtain informed consent) 
will be submitted, by the Investigator, to an IRB/IEC/REB. Approval from the IRB/IEC/REB 
must be obtained, and a copy must be provided to the Sponsor or its representatives before 
initiating the conduct of any study procedures including screening or enrolling any patients into 
the study. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 54 of 73 
No modifications or deviations from this protocol other than those that are deemed medically 
necessary by the Principal Investigator or designated sub-Investigator are to be made without 
prior, written approval by the Sponsor. Significant protocol deviations will be reported to the 
Sponsor and to the IRB/IEC/REB in accordance with its reporting policy. 
Any modifications made to the protocol by the Sponsor after receipt of IRB/IEC/REB approval 
must be submitted to the committee for approval prior to implementation. 
12.8. 
Written Informed Consent 
In accordance with regulatory and local IRB/IEC/REB requirements, before study procedures are 
performed, patients will be informed about the study and required to sign the IRB/IEC/REB 
approved Informed Consent Form (ICF). This form will be signed after adequate explanation of 
the aims, methods, objective and potential hazards of the study and prior to undertaking any 
study-related procedures. The Sponsor or its designee will provide an ICF template to the 
Investigator. The Sponsor or its designee must approve changes to the ICF template prior to 
submission to the IRB/IEC/REB. Informed consent will be obtained according to the applicable 
IRB/IEC/REB requirements. No patient is to be screened or treated until an ICF, written in a 
language in which the patient is fluent, has been obtained. The signed ICF will be retained with 
the study records. Each patient will also be given a copy of his/her signed ICF. 
12.9. 
Data Monitoring Committee (DMC) 
Not applicable. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 55 of 73 
13. 
DIRECT ACCESS TO SOURCE DATA/DOCUMENTS 
13.1. 
Study Monitoring 
In accordance with ICH-GCP guidelines, the study monitor must have direct access to the 
Investigator’s source documentation in order to verify the consistency of the data recorded in the 
electronic CRFs. 
The monitor is responsible for routine review of the electronic CRFs at regular intervals 
throughout the study, to verify adherence to the protocol, and the completeness, consistency and 
accuracy of the data being entered on them. The monitor should have full access to any subject 
records needed to verify the entries on the electronic CRFs. The Investigator agrees to cooperate 
with the monitor to assure that any follow-up items identified in the course of these monitoring 
visits are resolved. 
During site visits, the monitor will: 
• Check the progress of the study; 
• Review study data collected; 
• Conduct source document verification; 
• Identify any issues and address their resolution. 
This will be done in order to verify that the: 
• Data are authentic, accurate, and complete; 
• Safety and rights of subjects are being protected; 
• Study is conducted in accordance with the currently approved protocol (and any 
amendments), GCP, and all applicable regulatory requirements. 
The Investigator agrees to allow the monitor direct access to all relevant documents and to 
allocate his/her time and the time of his/her staff to the monitor to discuss findings and any 
relevant issues. 
13.2. 
Audits and Inspections 
Authorized representatives of the Sponsor, a regulatory authority, an Independent Ethics 
Committee or an Institutional Review Board may visit the site to perform audits or inspections, 
including source data verification. The purpose of a Sponsor audit or inspection is to 
systematically and independently examine all study-related activities and documents to 
determine whether these activities were conducted, and data were recorded, analyzed, and 
accurately reported according to the protocol, GCP guidelines of the ICH, and any applicable 
regulatory requirements. The Investigator should contact the Sponsor immediately if contacted 
by a regulatory agency about an inspection. 
13.3. 
Protocol Compliance 
The Investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 56 of 73 
13.4. 
Protocol Modifications 
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be 
made only by the Sponsor or its representatives. All protocol modifications must be submitted to 
the IRB/IEC/REB in accordance with local requirements. Approval must be obtained before 
changes can be implemented. 
13.5. 
Information Disclosure 
13.5.1. 
Ownership 
All information provided by the Sponsor or its representatives, and all data and information 
generated by the site as part of the study (other than a subject’s medical records), are the sole 
property of the Sponsor.  
13.5.2. 
Confidentiality 
All information provided by the Sponsor or its representatives, and all data and information 
generated by the site as part of the study (other than a subject’s medical records) will be kept 
confidential by the Investigator and other site staff. Information related to this study is subject to 
the confidentiality provisions of the Clinical Research Agreement between the investigative site 
and the Sponsor.  
13.5.3. 
Publication 
All publication or presentation rights for the findings of the clinical investigation under this 
protocol shall be governed by the appropriate terms of the Clinical Research Agreement between 
the investigational site and the Sponsor.  

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 57 of 73 
14. 
QUALITY CONTROL AND QUALITY ASSURANCE 
The study will be monitored and managed in accordance with ICH-GCP. 
To ensure compliance with GCP and all applicable regulatory requirements, the Sponsor or its 
representatives may conduct a quality assurance audit. Regulatory agencies may also conduct a 
regulatory inspection of this study. Such audits/inspections can occur at any time during or after 
completion of the study. If an audit or inspection occurs, the Investigator and institution agree to 
allow the auditor/inspector direct access to all relevant documents and to allocate his/her time 
and the time of his/her staff to the auditor/inspector to discuss findings and any relevant issues. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 58 of 73 
15. 
DATA HANDLING AND RECORDKEEPING 
15.1. 
Case Report Forms 
All required study data must be recorded on the electronic CRF provided by the Sponsor or its 
representatives. The data recorded onto the electronic CRF is derived from the source 
documents. The Investigator shall ensure that all data in the electronic CRF is accurate and 
consistent with the source documents or that any discrepancies of the electronic CRF with source 
documents are explained (ICH-GCP 4.9.2). 
Electronic case report forms will be accessed by the study center for collection of all study data, 
and a copy of the electronic CRF will be provided to the site for the Investigator files. For each 
subject, the electronic CRF must be completed by site staff and must be signed electronically by 
the Principal Investigator in a timely fashion after data collection. If a subject withdraws from 
the study, the electronic CRFs should be promptly completed and the reason for withdrawal must 
be noted. If a subject is withdrawn from the study because of a drug-related toxicity, thorough 
efforts should be made to clearly document the outcome. 
15.2. 
Retention/Inspection of Records 
The Investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. 
Records of drug receipt and disposition, electronic file of CRFs, source documents, reports of 
this investigation and other study documentation must be maintained by the Investigator for a 
period of at least 25 years following the date on which the investigational drug is approved by 
FDA or other applicable regulatory agency for marketing for the purposes that were the subject 
of the clinical investigations. If no application is to be filed, records must be retained until 25 
years following the date that the study is discontinued, and the FDA or other applicable 
regulatory agency is notified. If the application is not approved by the FDA or other applicable 
regulatory agency for such indication, records must be retained for 25 years after notification by 
the Sponsor of the FDA or other applicable regulatory agency decision. The records must be 
available for copying and inspection if requested by regulatory authorities. 
The Sponsor should be notified in writing at least 30 days prior to the disposal or transfer to 
another location or party of any study records related to this protocol. 
 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 59 of 73 
16. 
LIST OF REFERENCES 
Anderson CM, Sonis ST, Lee CM, Adkins D, Allen BG, Sun W, et al.. Phase 1b/2a Trial of the Superoxide Dismutase Mimetic 
GC4419 to Reduce Chemoradiotherapy- Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma. Int J 
Radiat Oncol Biol Physics 2017;100(2):427-435. 
Anderson CM, Lee CM, Saunders DP, et al.  Phase IIb randomized, double-blind trial of GC4419 versus placebo to reduce severe oral 
mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer.  J Clin Oncol 37:3256-3265, 2019. 
Anderson CM, Lee, CM, Saunders, D, et al.  "Tumor Outcomes of Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus 
Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer".  Head and Neck 
Cancer Symposium.  27-29 Feb. 2020.  The Westin Kierland Resort and Spa.  Scottsdale, Arizona. Presentation. 
Ang KK, Zhang Q-E, et al. Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without 
Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. J Clin Oncol 2014;32(27):2940-2950. 
Bodey GP, Rodriguez V, et al. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer 1978;41(4):1610-
1622. 
Bonner JA, Harari PM, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 
2006;354(6):567-578. 
Buettner GR, Ng CF, et al. A new paradigm: manganese superoxide dismutase influences the production of H2O2 in cells and thereby 
their biological state. Free radical biology & medicine 2006;41(8):1338-1350. 
Delanian S, Baillet F, et al. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical 
trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1994;32(1):12-20. 
Elting LS, Cooksley CD, et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck 
malignancies. International journal of radiation oncology, biology, physics 2007;68(4):1110-1120. 
Elting LS, Keefe DM, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with 
radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on 
quality of life. Cancer 2008;113(10):2704-2713. 
Epperly MW, Defilippi S, et al. Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects 
normal lung but not orthotopic tumors from irradiation. Gene therapy 2000;7(12):1011-1018. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 60 of 73 
Fakhry C, Zhang Q, Nguyen-Tan PF, et.al. Human Papillomavirus and Overall Survival After Progression of Oropharyngeal 
Squamous Cell Carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2014;32:3365-
3373. 
Galera clinical study report number U20-03-06-001 A Double-Blind, Placebo-Controlled, Single Rising Dose Study to Evaluate the 
Safety and Tolerability and Determine the Pharmacokinetics of M40419 Administered as a 15 Minute Intravenous Infusion in Healthy 
Subjects.  
Guo H, Seixas-Silva JA, Jr. et al. Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human 
manganese superoxide dismutase (SOD2) transgene. Radiation research 2003;159(3):361-370. 
Hahn T, Zhelnova E, et al. A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated 
with an increased risk of toxicity after autologous blood and marrow transplantation. Biology of blood and marrow transplantation : 
Journal of the American Society for Blood and Marrow Transplantation 2010;16(6):801-808. 
Henke M, Alfonsi M, et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for 
head and neck cancer: a randomized, placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 2011;29(20):2815-2820. 
Jacinto JCK, Co J, et.al. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally 
advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis. British Journal of Radiology 
2017;90:(1079). 
Keefe DM. Mucositis guidelines: what have they achieved, and where to from here? Supportive care in cancer : official journal of the 
Multinational Association of Supportive Care in Cancer 2006;14(6):489-491. 
Kudrimoti, M, Curtis A, et al. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the 
duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study." Journal of biotechnology 
2016;239:115-125. 
Lalla RV, Bowen J, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. 
Cancer 2014;120(10):1453-1461. 
Lalla RV, Peterson DE. Treatment of mucositis, including new medications. Cancer journal 2006;12(5):348-354. 
Le QT, Ki HEm, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: 
a randomized, placebo-controlled study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
2011;29(20):2808-2814. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 61 of 73 
McCord JM. Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). The Journal of biological 
chemistry 1969;244(22):6049-6055. 
Mendenhall WM, Amdur RJ, et al. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises 
and pitfalls. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(17):2618-2623. 
MuGard prescribing information. 
Murphy CK, Fey EG, et al. Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in 
hamsters. Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4292-4297. 
Nguyen-Tan PF, Zhang Q, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with 
concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy 
and toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014;32(34):3858-3866. 
Nonzee NJ, Dandade NA, et al. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : 
results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer 
patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer 
2008;113(6):1446-1452. 
Noronha V, Joshi A, et al. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and 
Neck Cancer: A Phase III Randomized Noninferiority Trial. Journal of clinical oncology: official journal of the American Society of 
Clinical Oncology 2018;36:1064-1072. 
Overgaard J, Hansen HS, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma 
of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362(9388): 933-940. 
Pignon JP, le Maitre A, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials 
and 17,346 patients. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 
2009;92(1):4-14. 
Rao NG, Trotti A, et al. Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for 
head and neck cancer. Oral oncology 2014;50(8):765-769. 
Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. International journal of radiation biology 
1994;65(1):27-33. 
Ruescher TJ, Sodeifi A, et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous 
bone marrow transplantation for hematologic malignancies. Cancer 1998;82(11):2275-2281. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 62 of 73 
Russo G, Haddad R, et al. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. The oncologist 
2008;13(8):886-898. 
Salama JK, Seiwert TY, et al. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol: Official journal of the 
American Society of Clinical Oncology 2007;25(26):4118-4126. 
Sonis S. and Galera Report no 1009-4419-0311 A Comparison of GC4419 and GC4403 for the Prevention of Oral Mucositis Induced 
by Acute Radiation in Hamsters. Biomodels Report Gal-03. 
Sonis S. and Galera Report no 1010-4419-0311 An Evaluation of GC4419 for the Prevention of Oral Mucositis Induced by 
Fractionated Radiation in Hamsters. Biomodels Report Gal-04. 
Sonis S, Haddad R, et al. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated 
with regimen-related toxicities in patients being treated for head and neck cancers. Oral oncology 2007;43(3):289-300. 
Sonis ST. The pathobiology of mucositis." Nature reviews. Cancer 4(4):277-284. 
Sonis ST. Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral oncology 2009;45(12):1015-1020. 
Sonis ST. Oral mucositis. Anti-cancer drugs 2011;22(7):607-612. 
Sonis S, Elting LS, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and 
consequences for patients. Cancer 2004;100(9 Suppl):1995-2025. 
Spielberger R, Stiff P, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. NEJM 2004;351(25):2590-
2598. 
Stojan P, Vermorken JB, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic 
review. Head Neck 2016;38:E2151-E2158. 
Sturtz P, Wouters K, et al. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in 
Locoregionally Advanced NonNasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. 
The Oncologist 2017;22:1056–1066. 
Thompson JS, Chu Y, et al. The manganese superoxide dismutase mimetic, M40403, protects adult mice from lethal total body 
irradiation. Free radical research 2010;44(5):529-540. 
Traynor AM, Richards GM, et al. Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of 
Wisconsin experience. Head & neck 2010;32(5):599-606. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 63 of 73 
Trotti A, Harris J, et al. NRG-RTOG 1016: Phase III Trial Comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related 
Cancer of the Oropharynx. International Journal of Radiation Oncology, Biology, Physics Supplement, 2018. 
Uno H, Claggett B, Tian L, et al. Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival 
Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014;32:2380-2385. 
Vera-Llonch M, Oster G, et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 
2006;106(2):329-336. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 64 of 73 
APPENDIX 1. SCHEDULE OF ASSESSMENTS 
Table 5: 
Schedule of Assessments 
Assessments 
Screening 
Treatment Period 
OM Follow-
Up 
≤28 days 
of IMRT 
Day 1 
Wk 1 
Wk 2 
Wk 3 
Wk 4 
Wk 5 
Wk 6 
Wk 7 
Last Day 
of IMRT 
or Early 
Term1 
Wks 1, 2, 3 
and 4  
(±2 D) 2 
Day 
1 
Days 
2-7 
Days  
8-14 
Days 
15-21 
Days 
22-28 
Days 
29-35 
Days 
36-42 
Days 
43-49 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion criteria3 
X 
X 
 
 
 
 
 
 
 
 
 
Dental exam/IMRT clearance 
X 
 
 
 
 
 
 
 
 
 
 
Medical and HNC histories4 
X 
 
 
 
 
 
 
 
 
 
 
Complete physical exam5 
X 
 
 
 
 
 
 
 
 
X 
 
Height 
X 
 
 
 
 
 
 
 
 
 
 
Weight 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
 
Vital signs, ECOG6 
X 
X 
 
 
 
X 
 
 
X 
X 
 
Record BSA7 
 
X 
 
X 
X 
X 
X 
X 
X 
 
 
Tumor imaging8 
X 
 
 
 
 
 
 
 
 
 
 
Concomitant medications9 
 
X 
Weekdays 
X 
X 
Adverse Events10 
 
X 
Weekdays 
X 
X 
ECG (12-lead)11 
X 
 
 
 
 
 
 
 
 
 
 
OM assessment12 
X 
X 
Twice-weekly 
X 
X 
Symptom Related Questionnaire 13  
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
Blood draw: Serum pregnancy14 
X 
 
 
 
 
 
 
 
 
X 
 
Blood draw: Lab safety tests15 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X16 
 
Blood draw: PK17 
 
X 
X 
 
 
X 
 
 
 
 
 
Urine Pregnancy Test18 
 
X 
 
 
 
X 
 
 
 
 
 
Dosing GC441919 
 
X 
Weekdays when IMRT is given 
X 
 
BSA = body surface area; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; HNC = head and neck cancer, IMRT = intensity-modulated radiation 
therapy; OM = oral mucositis; PE = physical examination; PK = pharmacokinetics 
Table footnotes 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 65 of 73 
1  If a subject ends study participation early and/or withdraws consent after Baseline (Day 1), all last day of IMRT procedures should be completed. 
2 The Post-IMRT OM and Safety Follow-up Visits will be scheduled based on the last day of IMRT. All subjects will be seen at Days 7, 14, 21 and 28 (± 2 
calendar days) from the last day of IMRT.  
3 See protocol Sections 7.1 and 7.2. 
4 The HNC history should include tumor HPV status, staging (AJCC 8th Edition) information, prior treatments, and confirmation of histopathological diagnosis 
of SCC. Medical conditions and illnesses that have occurred since the subject signed the ICF up until the date of enrollment should be recorded as medical 
history. Medical history also includes tobacco and alcohol use history. 
5 At the Screening and Last Day of IMRT Visits, a complete physical examination will be conducted. 
6 Vital signs (temperature, systolic and diastolic blood pressures, heart rate, and respiration rate), and ECOG will be obtained and recorded at the Screening and 
Baseline Visits, once during Weeks 4 and 7, and at the Last Day of IMRT Visit. All vital signs should be measured following 2 minutes of rest in the sitting 
position. On Day 1 (Baseline) and Day 22, blood pressure must be measured at the following times: 1) within 30 minutes prior to the pre-GC4419 PK draw, 
and 2) after GC4419 infusion, prior to standing and prior to the End of GC4419 Infusion PK draw. 
7 For subjects receiving tri-weekly cisplatin, body surface area (BSA) will be recorded to confirm cisplatin dosing at the Baseline Visit and once during Weeks 4 
and 7. For subjects receiving weekly cisplatin, BSA will be recorded to confirm cisplatin dosing at the Baseline Visit and once per week until chemotherapy is 
completed. 
8 Radiographic imaging must be performed within 60 days prior to the first day of IMRT for all subjects.  
9 All concomitant therapies (e.g., prescription and over-the-counter medications) taken by subjects on or after the date of enrollment through 30 days following 
the last dose of GC4419, IMRT or cisplatin (i.e. whichever occurs last) will be collected in the CRF. Any concomitant therapies used to treat any serious or 
related adverse event will be recorded in the CRF. 
10AEs and SAEs with onset dates on or after the date of enrollment through 30 days following the last dose of GC4419, IMRT or cisplatin (i.e. whichever occurs 
last) will be recorded on the CRF. All subjects with SAEs will be followed until the events resolve, stabilize, become chronic, the subject completes the study, 
or the subject is lost to follow-up.   
11 Ventricular rate and P-R, QRS, QT, and QTc intervals will be assessed and recorded at Screening. 
12 All OM assessments must be performed by trained evaluators. The extent of the subject’s OM will be scored using the WHO OM toxicity scale. OM 
assessments will be completed at the Screening Visit, at the Baseline Visit, twice weekly (no less than two days apart) within each 5-day IMRT period and on 
the last day of IMRT or Early Termination Visit. For Week 1, the first OM assessment will occur at the Baseline Visit and one additional OM assessment must 
occur at least two days later during the week. The extent of the subject’s OM will be scored using the WHO OM toxicity scale. OM assessments should 
continue weekly for four weeks following the last day of IMRT (Day 7, Day 14, Day 21 and Day 28 ± 2 calendar days).  
13 Symptom Related Questionnaires to be completed by subjects prior to the OM assessment at W1D1, and then prior to the second OM assessment each week 
and 28 days (± 2 calendar days) post end of treatment (EOT). 
14For a woman of childbearing potential, serum pregnancy test must be performed at the Screening Visit and at the Last Day of IMRT or Early Termination Visit. 
15 Clinical laboratory measurements will be conducted at the Screening Visit, twice during Week 1 (once at the Baseline Visit and again on Day 3, 4 or 5), and 
once weekly from Week 2 through the last day of IMRT. Clinical laboratory measurements at these visits will include the hematology profile (hemoglobin, 
hematocrit, red blood cell count, white blood cell count with differential, and platelet count. Differential to include total neutrophils, lymphocytes, monocytes, 
eosinophils, and basophils) and chemistry profile (glucose, BUN, creatinine, sodium, potassium, calcium, albumin, total protein, total bilirubin, direct bilirubin, 
alkaline phosphatase, ALT (SGPT), AST (SGOT), chloride, phosphate, bicarbonate, magnesium). 
16If safety labs have already been drawn during the study week in which the last day of IMRT or early termination visit falls, then lab safety tests (chemistry and 
hematology profiles) do not need to be conducted on the last day of IMRT or at the early termination visit. If safety labs have not been drawn during the current 
study week at the time of the early termination visit or on the last day of IMRT, then safety labs should be drawn on that day. Safety labs only need to be drawn 
once per study week after Week 1. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 66 of 73 
17Blood samples will be collected for GC4419 pharmacokinetic (PK) measurements at Baseline (Day 1), Day 2, and Day 22. See Section 10.5 for details. 
18 For women of childbearing potential, urine pregnancy tests should be administered at Baseline (Day 1) and Q4 weeks from enrollment.   
19 GC4419 will be administered up to 35 times: weekly, Monday through Friday, beginning at Baseline (IMRT Day 1) and continuing through the 35th dose. 
IMRT must begin no longer than four hours following the end of the GC4419 infusion. If IMRT is not received on any given day due to a treatment break or 
unforeseen circumstances, GC4419 should not be administered on that day. Subjects should resume GC4419 administration when IMRT resumes. If GC4419 
was already administered on a given day and IMRT is not administered due to unforeseen circumstances, that day’s GC4419 dose will still count as one of the 
35 doses.  
 
 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 67 of 73 
APPENDIX 2. 
WORLD HEALTH ORGANIZATION (WHO) SCORE OF 
ORAL MUCOSIT`IS  
Grade 
Scoring Criteria 
Grade 0: 
None 
Grade 1: 
Erythema and Soreness; No ulcers 
Grade 2: 
Ulcers; Able to eat a solid diet 
Grade 3: 
Ulcers; Requires a liquid diet 
Grade 4: 
Ulcers; Not able to tolerate a solid or liquid diet; Requires IV or tube feeding 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 68 of 73 
APPENDIX 3. PERFORMANCE STATUS CONVERSION 
Performance Status Conversion: ECOG - Karnofsky  
ECOG 
Karnofsky 
Score 
Description 
Score 
Description 
0 
Fully active, able to carry on all pre-
disease performances without 
restriction. 
100 
Normal, no complaints, no evidence of disease 
90 
Able to carry on normal activity, minor signs 
or symptoms of disease. 
1 
Restricted in physically strenuous 
activity, but ambulatory and able to 
carry out work of a light or 
sedentary nature, office work 
80 
Normal activity with effort, some signs or 
symptoms of disease 
70 
Cares for self, unable to carry on normal 
activity or do active work 
2 
Ambulatory and capable of all self-
care, but unable to carry out any 
work activities; Up and about more 
than 50% of waking hours 
60 
Requires occasional assistance, but is able to 
care for most of his/her needs 
50 
Requires considerable assistance and frequent 
medical care 
3 
Capable of only limited self-care, 
confined to bed or chair more than 
50% of waking hours 
40 
Disabled, requires special care and assistance 
30 
Severely disabled, hospitalization indicated; 
Death not imminent 
4 
Completely disabled; Cannot carry 
on any self-care; Totally confined to 
bed or chair 
20 
Very sick, hospital indicated, death not 
imminent 
10 
Moribund, fatal processes progressing rapidly 
5 
Death 
0 
Death 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 69 of 73 
APPENDIX 4. NATIONAL CANCER INSTITUTE-COMMON 
TERMINOLOGY CRITERIA FOR ADVERSE EVENTS, 
VERSION 5.0 
See the following website link for the complete NCI-CTCAE Version 5.0: 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_R
eference_8.5x11.pdf  

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 70 of 73 
APPENDIX 5. RECOMMENDED REGIMENS FOR HIGH-RISK 
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING 
(CINV) PER ASCO AND MASCC GUIDELINES 
Note: Both ASCO and MASCC define single-agent IV cisplatin as a “high risk” regimen for CINV. 
ASCO: http://ascopubs.org/doi/pdf/10.1200/JCO.2017.74.4789 
Table 6: 
Antiemetic Dosing for Adults – High Risk (Cisplatin) 
Drug Class 
Agent 
Dose on Day of 
Chemotherapy 
Dose(s) on 
Subsequent Days 
NK1 Receptor Antagonist 
Aprepitant 
125 mg oral 
80 mg oral; days 2 
and 3 
Fosaprepitant 
150 mg IV 
Day 1 only 
Netupitant-
palonosetron 
300 mg netupitant/0.5 mg 
palonosetron 
oral in single capsule (NEPA) 
Day 1 only 
Rolapitant 
180 mg oral 
Day 1 only 
5-HT3 Receptor Antagonist 
Granisetron 
2 mg oral OR 1 mg OR 0.01 
mg/kg IV OR 1 transdermal 
patch OR 10 mg SC 
Day 1 only 
Ondansetron 
8 mg oral twice daily OR 8 
mg oral dissolving tablet 
twice daily OR three 8 mg 
oral soluble films OR 8 mg 
or 0.15 mg/kg IV 
Palonosetron 
0.50 mg oral OR 0.25 mg IV 
 
Dolaseetron 
100 mg oral ONLY 
 
Tropisetron 
5 mg oral OR IV 
 
Ramosetron 
0.3 mg IV 
 
Corticosteroid if aprepitant is 
used* 
Dexamethasone 
12 mg oral OR IV 
8 mg oral OR IV; 
once daily on days 
2-4* 
Corticosteroid if 
fosaprepitant is used* 
Dexamethasone 
12 mg oral OR IV 
8 mg oral OR IV 
day 2; 8 mg oral 
OR IV twice daily 
on days 3-4* 
Corticosteroid if netupitant-
palonosetron is used* 
Dexamethasone 
12 mg oral OR IV 
8 mg oral OR IV; 
once daily on days 
2-4* 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 71 of 73 
Corticosteroid if rolapitant is 
used 
Dexamethasone 
20 mg oral OR IV 
8 mg oral OR IV; 
once daily on days 
2-4 
Olanzapine 
Olanzapine 
10 mg oral 
10 mg oral on 
days 2-4 
*Presumes patients are receiving an NK1 antagonist. If they are not, the dexamethasone dose should be adjusted 
to 20 mg on day 1 and 16 mg on days 2-4. 
 
MASCC: full updated guidelines may be found at: http://www.mascc.org/antiemetic-guidelines 
(2016)  
For the prevention of non-AC highly emetogenic chemotherapy, a three-drug regimen including 
single doses of a 5-HT3 RA, dexamethasone and an NK1 RA (aprepitant, fosaprepitant, 
netupitant or rolapitant), given before chemotherapy is recommended.  In patients receiving non-
AC highly emetogenic chemotherapy treated with a combination of an NK1 RA, a 5-HT3 RA 
and dexamethasone to prevent acute nausea and vomiting, dexamethasone on days 2–4 is 
suggested to prevent delayed nausea and vomiting.  If aprepitant 125 mg is used in day 1, then 
dexamethasone 8 mg x 1 (days 2-4) + aprepitant 80 mg x 1 (days 2-3) OR dexamethasone 8 mg 
x 2 (days 2-4) + metoclopramide 20 mg x 4 (days 2-4).   Please note that this dosage of 
metoclopramide derives from a phase III study and some regulatory authorities like EMA now 
recommend a maximum 0.5 mg/kg total daily dose. 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 72 of 73 
APPENDIX 6. DAILY ORAL CARE RECOMMENDATIONS 
The following protocol is strongly recommended for all dentulous or partially dentulous study 
participants to optimize oral health during radiation therapy and minimize the risk of post-
radiation dental sequelae. 
1. Diet – Minimize foods that contain refined sugars such as cookies, cakes, candy, sugar-
containing drinks, etc.  Favor fruits and vegetables. 
2. Avoid alcohol, tobacco products, and carbonated beverages. 
3. Practice scrupulous oral hygiene: 
a. Use a soft toothbrush or an electric toothbrush at least twice daily. 
b. Use fluoride-containing toothpaste or fluoride gel. When mouth becomes sore 
from mucositis continue to use toothbrush dipped in bland oral rinse. 
c. Clean spaces between the teeth using dental floss or similar device. 
d. If mouth is too sore to carry this out, rinse with topical anesthetic rinse to ensure 
completion of daily oral care. 
4. Chew sugarless chewing gum after meals. Avoid other forms of chewing gum. 
5. Use bland oral rinse three times a day until mouth becomes sore, then increase to every 
hour when mucositis begins. 
 
Recipe for bland oral rinse: 1 teaspoon salt and 1 teaspoon baking soda in 4 cups of water 
 

Clinical Study Protocol GTI-4419-202 
Galera Therapeutics, Inc. 
Confidential 
Version: 02Sep2020 
Page 73 of 73 
APPENDIX 7. SYMPTOM RELATED QUESTIONNAIRE